sulpiride and Schizophrenia studies

Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)
sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.

Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.

Research Excerpts

Excerpt	Relevance	Reference
"Although clozapine is an effective option for treatment-resistant schizophrenia (TRS), there are still 1/3 to 1/2 of TRS patients who do not respond to clozapine."	9.51	Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. ( Hu, QY; Huang, Y; Jin, Y; Li, ZZ; Liu, MJ; Liu, ZJ; Lv, QY; Shi, DH; Tan, HY; Wu, FC; Yang, JY; Yi, ZH; Zhao, L; Zhu, MH; Zhu, N, 2022)
"When treatment-refractory schizophrenia shows an insufficient response to a trial of clozapine, clinicians commonly add a second antipsychotic, despite the lack of robust evidence to justify this practice."	9.24	Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. ( Amos, T; Bagalkote, H; Barnes, TR; Davies, L; Fitzgerald, Z; Fridrich, P; Haddad, PM; Husni, M; Iqbal, K; Keown, P; Kumar, R; Leeson, VC; Marston, L; Osborn, D; Paton, C; Singh, V; Whittaker, W; Zafar, R, 2017)
"Only limited data are available on the effectiveness of augmented antipsychotics to clozapine therapy in chronic schizophrenia."	9.13	Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. ( Assion, HJ; Basilowski, M; Juckel, G; Lemanski, S; Reinbold, H, 2008)
"The beneficial effect of sulpiride augmentation of clozapine therapy for treatment-resistant schizophrenia patients is enhanced by its antisalivatory effect on clozapine-induced hypersalivation (CIH)."	9.12	Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. ( Kreinin, A; Novitski, D; Weizman, A, 2006)
"We compared the efficacy of ziprasidone and amisulpride in the treatment of negative symptoms and overall psychopathology in subjects who had chronic schizophrenia with predominantly negative symptoms."	9.12	Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. ( Murray, S; Olié, JP; Spina, E; Yang, R, 2006)
"To compare the efficacy and safety of amisulpride and olanzapine in subjects with schizophrenia and comorbid depression in a randomised double-blind trial."	9.12	A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. ( Douki, S; Vanelle, JM, 2006)
" We have assessed the evolution of body weight and glycaemia during a 6-month randomized comparative trial of amisulpride and olanzapine."	9.12	Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. ( De Hert, M; Mortimer, A; Peuskens, J, 2007)
"Both amisulpride and olanzapine produce sustained improvement in certain measures of neuropsychological performance in patients with schizophrenia; a significant improvement in score on the AVLT was observed only with amisulpride."	9.12	Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia. ( Balasubramaniam, K; Choudhary, PC; Joyce, E; Mortimer, AM; Saleem, PT, 2007)
"To determine the effectiveness of amisulpride on depression in patients with schizophrenia, in comparison to risperidone."	9.12	Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. ( Hwang, MY; Kim, JM; Kim, SW; Lee, JH; Lee, SH; Shin, IS; Yang, SJ; Yoon, BH; Yoon, JS, 2007)
"Treatment options are very limited for individuals with schizophrenia resistant to clozapine."	9.11	Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. ( Beer, MD; Cobb, AM; Kerwin, R; Launer, M; Matthiasson, P; Munro, J; Osborne, S; Purcell, S; Travis, M, 2004)
"To compare the efficacy and safety of the atypical antipsychotics amisulpride and olanzapine in the treatment of acute psychotic exacerbations of schizophrenia."	9.10	A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. ( Fleurot, O; Giudicelli, A; Lĵo, H; Martin, S; Peuskens, J; Rein, W; Thirumalai, S, 2002)
"This multicenter, double-blind, randomized study evaluated the efficacy, safety and functional effects of two atypical antipsychotics, amisulpride and risperidone, in patients with chronic schizophrenia (DSM IV) with a recent worsening of symptoms."	9.10	Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. ( Fleurot, O; Lecrubier, Y; Peuskens, J; Rein, W; Sechter, D, 2002)
"Amisulpride, a substituted benzamide with high selectivity for dopamine D3 and D2 receptors, was compared with the antipsychotic risperidone in patients with acute exacerbations of schizophrenia."	9.09	Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. ( Bale, R; Bech, P; Fleurot, O; Möller, HJ; Peuskens, J; Rein, W, 1999)
"Coadministration of olanzapine, an atypical neuroleptic, with sulpiride, a selective D2 antagonist, is suggested as an efficient strategy for treating patients with resistant unremitting schizophrenia."	9.09	Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia. ( Durst, R; Katz, G; Raskin, S; Zislin, J, 2000)
"In a multicentre, double-blind, flexible-dose study, 199 patients with paranoid schizophrenia or schizophreniform disorders received haloperidol (10-30 mg/d) or amisulpride (400-1200 mg/d) for four months."	9.09	Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). ( Bonhomme, D; Carrière, P; Lempérière, T, 2000)
" This study compared 800 mg/day amisulpride and 20 mg/day haloperidol in patients with acute exacerbations of schizophrenia."	9.08	Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. ( Boyer, P; Fleurot, O; Möller, HJ; Rein, W, 1997)
"Twenty-eight people with schizophrenia, previously unresponsive to typical antipsychotics and only partially responsive to current treatment with clozapine, received, double-blind, 600 mg/day sulpiride or placebo, in addition to an ongoing clozapine treatment."	9.08	Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. ( Aizenberg, D; Dorfman-Etrog, P; Khaikin, M; Modai, I; Radwan, M; Schwartz, B; Shiloh, R; Weizman, A; Zemishlany, Z, 1997)
"Seventeen patients with acute schizophrenia and 30 with chronic schizophrenia were included in a randomized, double-blind parallel-group trial comparing sulpiride and perphenazine."	9.06	Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial. ( Gordin, A; Koskinen, T; Lepola, U; Rimón, R; Salo, H, 1989)
"In a material of 71 patients admitted because of acute or chronic psychoses, 32 were treated with sulpiride (up to 1,800 mg per day) and 39 with chlorpromazine (up to 675 mg)."	9.04	Comparison of sulpiride and chlorpromazine in psychoses. A double-blind multicentre study. ( Bratfos, O; Haug, JO, 1979)
"Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels."	8.95	Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. ( Barber, S; Cipriani, A; Corsi, M; Olotu, U, 2017)
"To measure the outcomes (both beneficial and harmful) of the clinical effectiveness, safety and cost-effectiveness of oral fluphenazine versus atypical antipsychotics for schizophrenia."	8.93	Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. ( Furtado, VA; Li, BG; Sampford, JR; Sampson, S; Xia, J; Zhao, S, 2016)
"Sulpiride is a relatively old antipsychotic drug reputed to have a low incidence of adverse effects and an effect on the negative symptoms of schizophrenia."	8.90	Sulpiride versus placebo for schizophrenia. ( Sampson, S; Wang, J, 2014)
"When schizophrenia patients have insufficient response to clozapine, pharmacological augmentation is often applied."	8.88	Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. ( Begemann, MJ; Leucht, S; Sommer, IE; Temmerman, A, 2012)
"To evaluate the effects of risperidone compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychosis."	8.87	Risperidone versus other atypical antipsychotics for schizophrenia. ( Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2011)
"Sulpiride may be used in combination with other antipsychotic drugs in the hope of augmenting effectiveness - especially for those whose schizophrenia has proved resistant to treatment."	8.86	Sulpiride augmentation for schizophrenia. ( Fenton, M; Omori, IM; Soares, B; Wang, J, 2010)
"We included all randomised trials that used at least single-blind (rater-blind) design, comparing oral olanzapine with oral forms of amisulpride, aripiprazole, clozapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychosis."	8.86	Olanzapine versus other atypical antipsychotics for schizophrenia. ( Duggan, L; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2010)
"Sulpiride is a relatively old antipsychotic drug reputed to have low incidence of adverse effects and an effect on the negative symptoms of schizophrenia."	8.85	Sulpiride versus placebo for schizophrenia. ( Omori, IM; Wang, J, 2009)
"Although clozapine has been shown to be the treatment of choice in people with schizophrenia that are resistant to treatment, one third to two thirds of people still have persistent positive symptoms despite clozapine monotherapy of adequate dosage and duration."	8.85	Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. ( Barbui, C; Boso, M; Cipriani, A, 2009)
"We included all randomised, at least single-blind, controlled trials comparing oral ziprasidone with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone or zotepine in people with schizophrenia or schizophrenia-like psychoses."	8.85	Ziprasidone versus other atypical antipsychotics for schizophrenia. ( Bhoopathi, PS; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schwarz, S, 2009)
"The antipsychotic drug sulpiride was formulated over 20 years ago and was marked as having a low incidence of adverse effects and an effect on the negative symptoms of schizophrenia."	8.80	Sulpiride for schizophrenia. ( Chue, P; Fenton, M; Soares, BG, 2000)
"Sulpiride, which has selective dopaminergic blocking activity, is a substituted benzamide antipsychotic drug playing a prominent role in the treatment of schizophrenia, which more selective and primarily blocks dopamine D2 and D3 receptor."	7.96	In silico Analysis of Sulpiride, Synthesis, Characterization and In vitro Studies of its Nanoparticle for the Treatment of Schizophrenia. ( Akyuz, S; Bicak, B; Budama-Kilinc, Y; Cakir-Koc, R; Kaya, Z; Kecel-Gunduz, S; Kokcu, Y; Ozel, AE; Zorlu, T, 2020)
" Case description A 49-year-old man with schizophrenia, who was under maintenance treatment with olanzapine 20 mg/day, trihexyphenidyl 4 mg/day, and trazodone 50 mg/day, suffered from heat stroke in a heat wave and required intensive care."	7.81	Heat stroke during treatment with olanzapine, trihexyphenidyl, and trazodone in a patient with schizophrenia. ( Chang, CM; Chen, PJ; Lee, CP, 2015)
"The aim of the study was to investigate the prevalence rates of obsessive-compulsive disorder (OCD) and hypochondriasis in schizophrenic patients treated with atypical antipsychotics (AAPs) and to investigate the different comorbidity rates of OCD and hypochondriasis between clozapine-treated patients and patients treated with other AAPs."	7.80	Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics. ( Cantisani, A; Ferrari, G; Grassi, G; Pallanti, S; Poli, L; Righi, L, 2014)
"Clozapine is used in the management of treatment-resistant schizophrenia and is effective in reducing aggression; however a subgroup of patients is poorly responsive."	7.80	Augmentation of clozapine with amisulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a UK high-security hospital. ( Basu, A; Brooman-White, RS; Das, M; Gupta, N; Hotham, JE; Humphreys, SA; Larkin, F; Ross, CC; Simpson, PJ, 2014)
" We conducted this 6-month, parallel-group study to prospectively investigate the effects of the dopamine agonist cabergoline on sexual dysfunction in clinically stable patients with schizophrenia (DSM-IV, AP 194) and hyperprolactinemia (PRL > 20 ng/ml for men and PRL > 25 ng/ml for women)."	7.79	Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. ( Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E, 2013)
" We have previously shown altered synaptic plasticity in the hippocampal-NAc pathway in the methylazoxymethanol acetate (MAM) developmental model of schizophrenia in rodents that is dependent on cortical inputs."	7.79	Disruption of prefrontal cortical-hippocampal balance in a developmental model of schizophrenia: reversal by sulpiride. ( Belujon, P; Grace, AA; Patton, MH, 2013)
"We compared stable patients with schizophrenia who were treated with either amisulpride or olanzapine in terms of symptomatic outcome, neurocognitive functioning, functionality, and subjective outcome."	7.74	Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine. ( Bodner, T; Edlinger, M; Fleischhacker, WW; Hofer, A; Huber, R; Kemmler, G; Rettenbacher, MA; Sachs, G, 2007)
"Clozapine is the drug of choice for treatment-resistant schizophrenia."	7.74	Clozapine-induced myocarditis after long-term treatment: case presentation and clinical perspectives. ( Lang, UE; Malte Tugtekin, S; Matschke, K; Schmeisser, A; von Golitschek, R; Willbring, M, 2008)
"The Brief Psychiatric Rating Scale (BPRS) anxiety/depression subscore has been used to assess affective symptoms in three studies (n = 612) comparing amisulpride (400-800 mg/day, n = 339) with haloperidol (15-20 mg/day, n = 160) and risperidone (8 mg/day, n = 113) in the treatment of acute exacerbations of schizophrenia."	7.71	Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. ( Möller, HJ; Peuskens, J; Puech, A, 2002)
"A case of a pyoderma gangrenosum (PG)-like eruption due to the antipsychotic drug sulpiride, a form of risperidone, is described."	7.71	Suspected induction of a pyoderma gangrenosum-like eruption due to sulpiride treatment. ( Brenner, S; Shachar, E; Srebrnik, A, 2001)
"The relationship between erectile dysfunction and sulpiride stimulatory effect on prolactin secretion was studied in 13 married male psychiatric outpatients."	7.67	Sulpiride-induced hyperprolactinemia and impotence in male psychiatric outpatients. ( Asher, I; Ben-David, M; Maoz, B; Treves, I; Weizman, A, 1985)
"Tremor and insomnia were more frequent with amisulpride, while olanzapine caused more weight gain and sedation."	6.75	Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial. ( Bhowmick, S; Ghosh, M; Hazra, A, 2010)
"Hyperprolactinemia is an important but neglected adverse effect of antipsychotic medication."	6.73	Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. ( Chen, CH; Lu, ML; Shen, WW, 2008)
"This 4-week, double-blind, randomized study was undertaken to determine the dose-response relationship of amisulpride in 319 patients with acute exacerbation of schizophrenia."	6.69	Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. ( Fleurot, O; Puech, A; Rein, W, 1998)
" Following this, two dosage regiments, a morning only dose, and the same daily total dose in two equal fractions at 8 a."	6.65	Sulpiride trial in chronic schizophrenia with comparison of two dosage regimens. ( Bond, HR; Curry, SH; Lewis, DM, 1983)
"Sulpiride is a substituted benzamide with a selective action on receptors of the dopamine D2-like family, and clinical and pharmacological data suggest that it could be considered to be an atypical antipsychotic."	6.39	A risk-benefit assessment of sulpiride in the treatment of schizophrenia. ( Bitetto, A; Bravin, S; Invernizzi, G; Mauri, MC; Rudelli, R, 1996)
"Although clozapine is an effective option for treatment-resistant schizophrenia (TRS), there are still 1/3 to 1/2 of TRS patients who do not respond to clozapine."	5.51	Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. ( Hu, QY; Huang, Y; Jin, Y; Li, ZZ; Liu, MJ; Liu, ZJ; Lv, QY; Shi, DH; Tan, HY; Wu, FC; Yang, JY; Yi, ZH; Zhao, L; Zhu, MH; Zhu, N, 2022)
"Aripiprazole is a first or second line treatment frequently used because it has reduced side effects such as weight gain, sleepiness, dyslipidemia, insulin resistance, hyperprolactinemia and extrapyramidal symptoms."	5.43	[Aripiprazole, gambling disorder and compulsive sexuality]. ( Dafreville, C; Mété, D; Paitel, V; Wind, P, 2016)
"Sulpiride is a neuroleptic drug which is believed to block especially the non-adenylate cyclase dopaminergic receptors which are supposed to be inhibitory axoaxonic receptors on glutamatergic corticostriatal terminals."	5.27	Cerebral glutamate, neuroleptic drugs and schizophrenia: increase of cerebrospinal fluid glutamate levels and decrease of striate body glutamate levels following sulpiride treatment in rats. ( Claus, D; Kim, JS; Kornhuber, HH, 1983)
"When treatment-refractory schizophrenia shows an insufficient response to a trial of clozapine, clinicians commonly add a second antipsychotic, despite the lack of robust evidence to justify this practice."	5.24	Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. ( Amos, T; Bagalkote, H; Barnes, TR; Davies, L; Fitzgerald, Z; Fridrich, P; Haddad, PM; Husni, M; Iqbal, K; Keown, P; Kumar, R; Leeson, VC; Marston, L; Osborn, D; Paton, C; Singh, V; Whittaker, W; Zafar, R, 2017)
"Our results are consistent with those of a similar post-hoc analysis of hostility in first-episode subjects with schizophrenia enrolled in the European First-Episode Schizophrenia Trial (EUFEST) trial, where olanzapine demonstrated advantages compared with haloperidol, quetiapine, and amisulpride."	5.19	Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. ( Citrome, L; Czobor, P; Van Dorn, RA; Volavka, J, 2014)
" This study aimed to compare the efficacy and safety of low-dose amisulpride plus low-dose sulpiride with full-dose amisulpride in the treatment of acute schizophrenia."	5.17	Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study. ( Chen, CC; Huang, YH; Lane, HY; Lin, CH; Lin, SC; Wang, FC, 2013)
"The study was designed as a 6-week, two-center, fixed-dose, comparison study of 400 mg/day of amisulpride versus 300 mg/day of moclobemide as an adjunctive treatment in 53 schizophrenia and schizoaffective disorder patients (diagnosed according to DSM-IV) suffering from CIS."	5.15	Amisulpride versus moclobemide in treatment of clozapine-induced hypersalivation. ( Bergman, J; Kreinin, A; Lerner, V; Libov, I; Miodownik, C; Shestakova, D; Sokolik, S, 2011)
"To compare the effects of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on hostility in first-episode schizophrenia, schizoaffective disorder, or schizophreniform disorder."	5.15	Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). ( Bitter, I; Czobor, P; Derks, EM; Fleischhacker, WW; Kahn, RS; Libiger, J; Volavka, J, 2011)
"The primary objective of this randomised, active-controlled, parallel group, double-blind study was to evaluate the tolerability of treatment with either amisulpride or risperidone in elderly patients with schizophrenia aged over 65 years; evaluation of efficacy was a secondary objective."	5.14	A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients. ( Eich, FX; Möller, HJ; Riedel, M, 2009)
"Only limited data are available on the effectiveness of augmented antipsychotics to clozapine therapy in chronic schizophrenia."	5.13	Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. ( Assion, HJ; Basilowski, M; Juckel, G; Lemanski, S; Reinbold, H, 2008)
"The beneficial effect of sulpiride augmentation of clozapine therapy for treatment-resistant schizophrenia patients is enhanced by its antisalivatory effect on clozapine-induced hypersalivation (CIH)."	5.12	Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. ( Kreinin, A; Novitski, D; Weizman, A, 2006)
"We compared the efficacy of ziprasidone and amisulpride in the treatment of negative symptoms and overall psychopathology in subjects who had chronic schizophrenia with predominantly negative symptoms."	5.12	Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. ( Murray, S; Olié, JP; Spina, E; Yang, R, 2006)
"The present study aimed to investigate the effects of clozapine, olanzapine, risperidone, and sulpiride on glucose and lipid metabolism in first-episode schizophrenia."	5.12	Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. ( Guo, WB; Guo, XF; Liu, ZN; Tang, JS; Wu, RR; Zhai, JG; Zhao, JP, 2006)
" We conducted a prospective, open study in schizophrenia patients in order to compare body weight and serum lipids during treatment with amisulpride, ziprasidone, clozapine or olanzapine over a period of 4 weeks."	5.12	Early changes of plasma lipids during treatment with atypical antipsychotics. ( Baumgartner, S; Ebenbichler, C; Edlinger, M; Fleischhacker, WW; Hofer, A; Hummer, M; Kemmler, G; Lechleitner, M; Rettenbacher, MA, 2006)
"To compare the efficacy and safety of amisulpride and olanzapine in subjects with schizophrenia and comorbid depression in a randomised double-blind trial."	5.12	A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. ( Douki, S; Vanelle, JM, 2006)
" We have assessed the evolution of body weight and glycaemia during a 6-month randomized comparative trial of amisulpride and olanzapine."	5.12	Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. ( De Hert, M; Mortimer, A; Peuskens, J, 2007)
"Both amisulpride and olanzapine produce sustained improvement in certain measures of neuropsychological performance in patients with schizophrenia; a significant improvement in score on the AVLT was observed only with amisulpride."	5.12	Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia. ( Balasubramaniam, K; Choudhary, PC; Joyce, E; Mortimer, AM; Saleem, PT, 2007)
"To determine the effectiveness of amisulpride on depression in patients with schizophrenia, in comparison to risperidone."	5.12	Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. ( Hwang, MY; Kim, JM; Kim, SW; Lee, JH; Lee, SH; Shin, IS; Yang, SJ; Yoon, BH; Yoon, JS, 2007)
"Treatment options are very limited for individuals with schizophrenia resistant to clozapine."	5.11	Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. ( Beer, MD; Cobb, AM; Kerwin, R; Launer, M; Matthiasson, P; Munro, J; Osborne, S; Purcell, S; Travis, M, 2004)
"To compare the efficacy and safety of the atypical antipsychotics amisulpride and olanzapine in the treatment of acute psychotic exacerbations of schizophrenia."	5.10	A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. ( Fleurot, O; Giudicelli, A; Lĵo, H; Martin, S; Peuskens, J; Rein, W; Thirumalai, S, 2002)
"This multicenter, double-blind, randomized study evaluated the efficacy, safety and functional effects of two atypical antipsychotics, amisulpride and risperidone, in patients with chronic schizophrenia (DSM IV) with a recent worsening of symptoms."	5.10	Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. ( Fleurot, O; Lecrubier, Y; Peuskens, J; Rein, W; Sechter, D, 2002)
"This study suggests that amisulpride is as effective as risperidone in the treatment of patients with schizophrenia."	5.10	Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan. ( Chen, YS; Hwang, TJ; Lee, SM; Lee, YC; Lin, HN; Sun, HJ; Tsai, SJ, 2003)
"Amisulpride, a substituted benzamide with high selectivity for dopamine D3 and D2 receptors, was compared with the antipsychotic risperidone in patients with acute exacerbations of schizophrenia."	5.09	Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. ( Bale, R; Bech, P; Fleurot, O; Möller, HJ; Peuskens, J; Rein, W, 1999)
" In this long-term, open, randomised, multicentre trial, patients with chronic or subchronic schizophrenia received amisulpride (n =370) or haloperidol (n = 118) for 12 months."	5.09	Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. ( Colonna, L; Dondey-Nouvel, L; Rein, W; Saleem, P, 2000)
"Coadministration of olanzapine, an atypical neuroleptic, with sulpiride, a selective D2 antagonist, is suggested as an efficient strategy for treating patients with resistant unremitting schizophrenia."	5.09	Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia. ( Durst, R; Katz, G; Raskin, S; Zislin, J, 2000)
"In a multicentre, double-blind, flexible-dose study, 199 patients with paranoid schizophrenia or schizophreniform disorders received haloperidol (10-30 mg/d) or amisulpride (400-1200 mg/d) for four months."	5.09	Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). ( Bonhomme, D; Carrière, P; Lempérière, T, 2000)
" This study compared 800 mg/day amisulpride and 20 mg/day haloperidol in patients with acute exacerbations of schizophrenia."	5.08	Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. ( Boyer, P; Fleurot, O; Möller, HJ; Rein, W, 1997)
"Twenty-eight people with schizophrenia, previously unresponsive to typical antipsychotics and only partially responsive to current treatment with clozapine, received, double-blind, 600 mg/day sulpiride or placebo, in addition to an ongoing clozapine treatment."	5.08	Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. ( Aizenberg, D; Dorfman-Etrog, P; Khaikin, M; Modai, I; Radwan, M; Schwartz, B; Shiloh, R; Weizman, A; Zemishlany, Z, 1997)
"Seventeen patients with acute schizophrenia and 30 with chronic schizophrenia were included in a randomized, double-blind parallel-group trial comparing sulpiride and perphenazine."	5.06	Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial. ( Gordin, A; Koskinen, T; Lepola, U; Rimón, R; Salo, H, 1989)
"In a material of 71 patients admitted because of acute or chronic psychoses, 32 were treated with sulpiride (up to 1,800 mg per day) and 39 with chlorpromazine (up to 675 mg)."	5.04	Comparison of sulpiride and chlorpromazine in psychoses. A double-blind multicentre study. ( Bratfos, O; Haug, JO, 1979)
"Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels."	4.95	Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. ( Barber, S; Cipriani, A; Corsi, M; Olotu, U, 2017)
"To measure the outcomes (both beneficial and harmful) of the clinical effectiveness, safety and cost-effectiveness of oral fluphenazine versus atypical antipsychotics for schizophrenia."	4.93	Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. ( Furtado, VA; Li, BG; Sampford, JR; Sampson, S; Xia, J; Zhao, S, 2016)
"Sulpiride is a relatively old antipsychotic drug reputed to have a low incidence of adverse effects and an effect on the negative symptoms of schizophrenia."	4.90	Sulpiride versus placebo for schizophrenia. ( Sampson, S; Wang, J, 2014)
"When schizophrenia patients have insufficient response to clozapine, pharmacological augmentation is often applied."	4.88	Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. ( Begemann, MJ; Leucht, S; Sommer, IE; Temmerman, A, 2012)
"To evaluate the effects of risperidone compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychosis."	4.87	Risperidone versus other atypical antipsychotics for schizophrenia. ( Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2011)
"We included randomised, at least single-blind, trials comparing oral amisulpride with oral forms of aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychoses."	4.86	Amisulpride versus other atypical antipsychotics for schizophrenia. ( Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S; Silveira da Mota Neto, JI, 2010)
"Sulpiride may be used in combination with other antipsychotic drugs in the hope of augmenting effectiveness - especially for those whose schizophrenia has proved resistant to treatment."	4.86	Sulpiride augmentation for schizophrenia. ( Fenton, M; Omori, IM; Soares, B; Wang, J, 2010)
"We included all randomised trials that used at least single-blind (rater-blind) design, comparing oral olanzapine with oral forms of amisulpride, aripiprazole, clozapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychosis."	4.86	Olanzapine versus other atypical antipsychotics for schizophrenia. ( Duggan, L; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2010)
" Olanzapine produced more weight gain than all other second-generation antipsychotics except for clozapine where no difference was found."	4.86	Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. ( Davis, JM; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Lobos, CA; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2010)
"Sulpiride is a relatively old antipsychotic drug reputed to have low incidence of adverse effects and an effect on the negative symptoms of schizophrenia."	4.85	Sulpiride versus placebo for schizophrenia. ( Omori, IM; Wang, J, 2009)
"Although clozapine has been shown to be the treatment of choice in people with schizophrenia that are resistant to treatment, one third to two thirds of people still have persistent positive symptoms despite clozapine monotherapy of adequate dosage and duration."	4.85	Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. ( Barbui, C; Boso, M; Cipriani, A, 2009)
"We included all randomised, at least single-blind, controlled trials comparing oral ziprasidone with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone or zotepine in people with schizophrenia or schizophrenia-like psychoses."	4.85	Ziprasidone versus other atypical antipsychotics for schizophrenia. ( Bhoopathi, PS; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schwarz, S, 2009)
"The antipsychotic drug sulpiride was formulated over 20 years ago and was marked as having a low incidence of adverse effects and an effect on the negative symptoms of schizophrenia."	4.80	Sulpiride for schizophrenia. ( Chue, P; Fenton, M; Soares, BG, 2000)
"To review the pharmacology, pharmacokinetics, clinical investigations, and adverse effects of sulpiride as a treatment for schizophrenia."	4.79	Sulpiride: an antipsychotic with selective dopaminergic antagonist properties. ( Caley, CF; Weber, SS, 1995)
"Aminosulpiride is a benzamide used to treat acute or chronic schizophrenia Some researchers believe that early improvement of depression symptoms in patients has a certain predictive effect on the recovery of symptoms after drug treatment for schizophrenia."	3.96	Prediction of the significance in the improvement of depression symptoms of amisulpride in the treatment of schizophrenia: an 8-week case-control study. ( Ni, Y; Pan, A; Wang, G; Zheng, L; Zhou, B, 2020)
"Sulpiride, which has selective dopaminergic blocking activity, is a substituted benzamide antipsychotic drug playing a prominent role in the treatment of schizophrenia, which more selective and primarily blocks dopamine D2 and D3 receptor."	3.96	In silico Analysis of Sulpiride, Synthesis, Characterization and In vitro Studies of its Nanoparticle for the Treatment of Schizophrenia. ( Akyuz, S; Bicak, B; Budama-Kilinc, Y; Cakir-Koc, R; Kaya, Z; Kecel-Gunduz, S; Kokcu, Y; Ozel, AE; Zorlu, T, 2020)
"To investigate the clinical effects of aripiprazole on sexual dysfunction induced by amisulpride or risperidone in male patients with schizophrenia."	3.85	[Aripiprazole for drug-induced sexual dysfunction in schizophrenic males]. ( Gao, LJ; Guo, HG; Liang, ZT; Yang, Y; Zhong, XX; Zhu, JC, 2017)
"To investigate the role of SGA treatment on neural processing related to OCS in patients with schizophrenia, we stratified patients according to their monotherapy into 2 groups (group I: clozapine or olanzapine; group II: amisulpride or aripiprazole)."	3.81	Increased orbitofrontal cortex activation associated with "pro-obsessive" antipsychotic treatment in patients with schizophrenia. ( Eifler, S; Englisch, S; Esslinger, C; Kirsch, P; Meyer-Lindenberg, A; Mier, D; Rausch, F; Schirmbeck, F; Zink, M, 2015)
"The addition of amisulpride could lead to an improvement in schizophrenia symptoms in patients that do not, or only partially, respond to risperidone."	3.81	Augmentation with amisulpride for schizophrenic patients non-responsive to risperidone monotherapy. ( Amorin-Díaz, M; Aparicio-Castro, E; López-Rodríguez, E; Molina, JD; Muñoz Algar, MJ; Toledo-Romero, F, 2015)
"Clozapine monotherapy is clearly the optimal medication in medication refractory schizophrenia and it is possible to maximise its use."	3.81	Skating on thin ice: pragmatic prescribing for medication refractory schizophrenia. ( Joyce, DW; Mateos Fernandez, MJ; Sarkar, SN; Shergill, SS; Tracy, DK, 2015)
" Case description A 49-year-old man with schizophrenia, who was under maintenance treatment with olanzapine 20 mg/day, trihexyphenidyl 4 mg/day, and trazodone 50 mg/day, suffered from heat stroke in a heat wave and required intensive care."	3.81	Heat stroke during treatment with olanzapine, trihexyphenidyl, and trazodone in a patient with schizophrenia. ( Chang, CM; Chen, PJ; Lee, CP, 2015)
"The aim of the study was to investigate the prevalence rates of obsessive-compulsive disorder (OCD) and hypochondriasis in schizophrenic patients treated with atypical antipsychotics (AAPs) and to investigate the different comorbidity rates of OCD and hypochondriasis between clozapine-treated patients and patients treated with other AAPs."	3.80	Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics. ( Cantisani, A; Ferrari, G; Grassi, G; Pallanti, S; Poli, L; Righi, L, 2014)
"Clozapine is used in the management of treatment-resistant schizophrenia and is effective in reducing aggression; however a subgroup of patients is poorly responsive."	3.80	Augmentation of clozapine with amisulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a UK high-security hospital. ( Basu, A; Brooman-White, RS; Das, M; Gupta, N; Hotham, JE; Humphreys, SA; Larkin, F; Ross, CC; Simpson, PJ, 2014)
"One hundred and sixty-three first-episode inpatients with schizophrenia were recruited, to whom one of three conventional antipsychotics (perphenazine, sulpiride, and chlorpromazine) or one of three atypical antipsychotics (clozapine, quetiapine, and aripiprazole) was prescribed for 12 months as appropriate."	3.80	Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study. ( Cao, B; Hou, R; Jian, J; Mi, G; Qiu, H; Tang, M; Wang, M, 2014)
"A 19-year-old man with schizophrenia and underlying cerebral disease developed rapid-onset mania after risperidone was replaced with amisulpride."	3.80	Amisulpride-associated mania in a young adult with schizophrenia and cerebral disease. ( Chen, CY; Chen, TY; Chuang, WC; Kuo, SC; Yeh, YW, 2014)
" Amisulpiride, a second generation antipsychotic drug is used in the treatment of schizophrenia and psychotic depression."	3.79	Safety of the electroconvulsive therapy and amisulpride combination. ( Gazdag, G; Iványi, Z; Takács, R; Ungvari, GS, 2013)
" We conducted this 6-month, parallel-group study to prospectively investigate the effects of the dopamine agonist cabergoline on sexual dysfunction in clinically stable patients with schizophrenia (DSM-IV, AP 194) and hyperprolactinemia (PRL > 20 ng/ml for men and PRL > 25 ng/ml for women)."	3.79	Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. ( Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E, 2013)
" We have previously shown altered synaptic plasticity in the hippocampal-NAc pathway in the methylazoxymethanol acetate (MAM) developmental model of schizophrenia in rodents that is dependent on cortical inputs."	3.79	Disruption of prefrontal cortical-hippocampal balance in a developmental model of schizophrenia: reversal by sulpiride. ( Belujon, P; Grace, AA; Patton, MH, 2013)
"Since oxidative stress observed in schizophrenia may be caused partially by the treatment of patients with various antipsychotics, the aim of the study was to establish the effects of beta-d-glucan, polysaccharide derived from the yeast cell walls of species such as Saccharomyces cerevisiae, and the antipsychotics (the first generation antipsychotic (FGA) - haloperidol and the second generation antipsychotic (SGA) - amisulpride) action on plasma lipid peroxidation in vitro."	3.77	Beta-glucan from Saccharomyces cerevisiae reduces plasma lipid peroxidation induced by haloperidol. ( Dietrich-Muszalska, A; Kontek, B; Olas, B; Rabe-Jabłońska, J, 2011)
"We stratified 70 patients with schizophrenia according to their mode of antipsychotic treatment: clozapine and olanzapine (group I) compared with aripiprazole and amisulpride (group II)."	3.77	Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. ( Englisch, S; Esslinger, C; Meyer-Lindenberg, A; Rausch, F; Schirmbeck, F; Zink, M, 2011)
"Compared to traditional neuroleptics, most of the new antipsychotics are characterized by a low extrapyramidal side effect (EPS) liability and varying antipsychotic efficacy."	3.77	New antipsychotics: classification, efficacy, and adverse effects. ( Gerlach, J, 1991)
"In this study, 11 healthy male subjects taking different doses of sulpiride and 24 male patients with DSM-IV-diagnosed schizophrenia taking different antipsychotic drugs (risperidone, olanzapine, haloperidol, and sulpiride) participated."	3.76	Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. ( Arakawa, R; Ito, H; Maeda, J; Okubo, Y; Okumura, M; Suhara, T; Takahashi, H; Takano, A; Takano, H, 2010)
" We conducted a prospective, open study comparing body weight, parameters of insulin resistance in schizophrenia patients treated with either clozapine (n = 10) or amisuLpride ( n = 12)."	3.74	Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study. ( Baumgartner, S; Ebenbichler, C; Edlinger, M; Hofer, A; Hummer, M; Kemmler, G; Lechleitner, M; Rettenbacher, MA; Wolfgang Fleischhacker, W, 2007)
"We compared stable patients with schizophrenia who were treated with either amisulpride or olanzapine in terms of symptomatic outcome, neurocognitive functioning, functionality, and subjective outcome."	3.74	Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine. ( Bodner, T; Edlinger, M; Fleischhacker, WW; Hofer, A; Huber, R; Kemmler, G; Rettenbacher, MA; Sachs, G, 2007)
" Patients aged 2 18 years who received an initial prescription for olanzapine, risperidone, quetiapine or amisulpride between April 1 and September 30, 2003; and had an ICD-10-coded diagnosis of schizophrenia were included."	3.74	Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis. ( Hui, HY; Law, WL; You, JH; Young, WM, 2007)
"Clozapine is the drug of choice for treatment-resistant schizophrenia."	3.74	Clozapine-induced myocarditis after long-term treatment: case presentation and clinical perspectives. ( Lang, UE; Malte Tugtekin, S; Matschke, K; Schmeisser, A; von Golitschek, R; Willbring, M, 2008)
"Clozapine had a significantly lower discontinuation rate in individuals with schizophrenia, compared to the other 4 SGAs."	3.74	Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. ( Lawrie, SM; Shajahan, P; Taylor, M, 2008)
"The Brief Psychiatric Rating Scale (BPRS) anxiety/depression subscore has been used to assess affective symptoms in three studies (n = 612) comparing amisulpride (400-800 mg/day, n = 339) with haloperidol (15-20 mg/day, n = 160) and risperidone (8 mg/day, n = 113) in the treatment of acute exacerbations of schizophrenia."	3.71	Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. ( Möller, HJ; Peuskens, J; Puech, A, 2002)
"A case of a pyoderma gangrenosum (PG)-like eruption due to the antipsychotic drug sulpiride, a form of risperidone, is described."	3.71	Suspected induction of a pyoderma gangrenosum-like eruption due to sulpiride treatment. ( Brenner, S; Shachar, E; Srebrnik, A, 2001)
"During clinical experience with the "atypical" neuroleptic drugs clozapine, risperidone, and zotepine, some patients have shown a marked weight gain."	3.70	Weight gain: side effect of atypical neuroleptics? ( Müssigbrodt, HE; Wetterling, T, 1999)
"The relationship between erectile dysfunction and sulpiride stimulatory effect on prolactin secretion was studied in 13 married male psychiatric outpatients."	3.67	Sulpiride-induced hyperprolactinemia and impotence in male psychiatric outpatients. ( Asher, I; Ben-David, M; Maoz, B; Treves, I; Weizman, A, 1985)
" Nine patients discontinued treatment because of adverse events."	2.82	The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8-week, prospective, open-label, multicenter, single-arm study. ( Cao, C; Chen, Z; Deng, H; Dong, F; Gao, M; Hong, L; Li, X; Li, Y; Liang, Y; Liu, T; Lu, S; Su, L; Tang, J; Tang, M; Wang, C; Wang, X; Xie, S; Xin, L; Xu, X; Yang, F; Yu, J; Yu, X; Zhang, C; Zhang, Y; Zhu, C, 2016)
"We have investigated the categorical prevalence of hyperprolactinemia and examined the relationship between prolactin levels and subjective endocrine-related adverse effects in schizophrenia patients treated with amisulpride during a 1-year period."	2.77	Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride. ( Ahn, YM; Jung, DC; Kim, EY; Kim, SH; Kim, YS; Lee, NY, 2012)
"Tremor and insomnia were more frequent with amisulpride, while olanzapine caused more weight gain and sedation."	2.75	Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial. ( Bhowmick, S; Ghosh, M; Hazra, A, 2010)
"Hyperprolactinemia is an important but neglected adverse effect of antipsychotic medication."	2.73	Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. ( Chen, CH; Lu, ML; Shen, WW, 2008)
"The trial was a prospective, open-label, single-center one with a flexible dosing of SGAs."	2.73	Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. ( Cejpková, A; Rodáková, I; Svestka, J; Synek, O; Tomanová, J, 2007)
" Analyses of CFA-derived factor scores showed that ASP was significantly superior to FPX regarding the latent 'depressive' dimension, independent of baseline scores, dosage and changes in akinesia."	2.70	Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: an evaluation using confirmatory factor analysis. ( Benkert, O; Müller, MJ; Wetzel, H, 2002)
"Flupenthixol treatment initially raised the prolactin levels about two- or threefold, and a subsequent decline during months 3 and 6 occurred."	2.70	Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. ( Anghelescu, I; Benkert, O; Ewald-Gründer, S; Gründer, G; Hiemke, C; Hillert, A; Schlösser, R, 2002)
"The present analysis investigated symptom-specific dose-response relationships of the atypical antipsychotic amisulpride (AMI) in schizophrenic patients."	2.70	Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia. ( Benkert, O; Eich, FX; Müller, MJ; Puech, A; Rein, W; Wetzel, H, 2002)
" In an open pilot study, we investigated 26 inpatients (13 female, 13 male) with schizophrenic or depressive disorder treated with SULP (mean daily dosage 64-1062 mg) administered orally, either as a monotherapy or as an add-on treatment to a stable and unchanged medication for 3-60 days."	2.70	Serum levels of sulpiride enantiomers after oral treatment with racemic sulpiride in psychiatric patients: a pilot study. ( Härtter, S; Hiemke, C; Köhler, D; Müller, MJ, 2001)
"m."	2.70	Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. ( Hatzimanolis, J; Lykouras, L; Markianos, M, 2001)
"This 4-week, double-blind, randomized study was undertaken to determine the dose-response relationship of amisulpride in 319 patients with acute exacerbation of schizophrenia."	2.69	Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. ( Fleurot, O; Puech, A; Rein, W, 1998)
" The drug had only a limited effect in reducing negative symptoms, which were relatively stable, enduring phenomena in this sample, despite dosage reduction."	2.68	One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. ( Alberts, JL; Barnes, TR; Curson, DA; Pantelis, C; Speller, JC, 1997)
"Sulpiride was administered in three different daily dosages (400, 800 or 1200 mg) according to a double dummy blind randomized administration schedule."	2.67	Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenic patients. ( Alfredsson, G; Wiesel, FA, 1990)
"Sulpiride was administered in three different daily dosages (starting with 400, 800 or 1200 mg) according to a double blind randomized administration schedule."	2.66	Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. ( Alfredsson, G; Wiesel, FA, 1989)
"Sulpiride was the only drug that increased the number of dose-dependent symptom-free days."	2.66	Prophylactic effects of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of timiperone and sulpiride. ( Koga, I; Nishikawa, T; Tanaka, M; Tsuda, A; Uchida, Y, 1989)
"Sulpiride was superior to CPZ in reducing the autistic symptoms."	2.66	Effects of sulpiride and chlorpromazine on autistic and positive psychotic symptoms in schizophrenic patients--relationship to drug concentrations. ( Alfredsson, G; Härnryd, C; Wiesel, FA, 1985)
"Sulpiride-treated patients with extrapyramidal side effects had significantly higher drug concentrations in serum."	2.65	Relationships between drug concentrations in serum and CSF, clinical effects and monoaminergic variables in schizophrenic patients treated with sulpiride or chlorpromazine. ( Alfredsson, G; Bjerkenstedt, L; Edman, G; Härnryd, C; Oxenstierna, G; Sedvall, G; Wiesel, FA, 1984)
"Treatment with sulpiride or chlorpromazine resulted in a significant reduction of psychotic morbidity as estimated by CPRS and global ratings."	2.65	Clinical evaluation of sulpiride in schizophrenic patients--a double-blind comparison with chlorpromazine. ( Aberg-Wistedt, A; Bjerkenstedt, L; Björk, K; Gullberg, B; Härnryd, C; Oxenstierna, G; Sedvall, G; Wiesel, FA; Wik, G, 1984)
" Following this, two dosage regiments, a morning only dose, and the same daily total dose in two equal fractions at 8 a."	2.65	Sulpiride trial in chronic schizophrenia with comparison of two dosage regimens. ( Bond, HR; Curry, SH; Lewis, DM, 1983)
"Treatment with sulpiride was associated with a significant rise in plasma prolactin level, but paradoxically these patients had significantly reduced extrapyramidal symptoms."	2.65	A clinical and pharmacodynamic evaluation of sulpiride. ( Bailey, J; Bishop, M; Coppen, A; Rao, VA, 1981)
"Sulpiride is a new and chemically different neuroleptic."	2.64	An evaluation of a unique new antipsychotic agent, sulpiride: effects on serum prolactin and growth hormone levels. ( Gallant, DM; Kessler, C; Mielke, DH, 1977)
"Sulpiride is a new antipsychotic agent chemically different from recognized psychotropic compounds."	2.64	Sulpiride: evaluation of antipsychotic activity in schizophrenic patients. ( Gallant, DM; Kessler, C; Kessler, LR; Mielke, DH; Roniger, JJ, 1977)
" The daily dosage varied from 300 to 1,200 mg Sulpiride orally and 12 to 48 mg Perphenazine."	2.64	[Study of the clinical effects of sulpiride and perphenazine in 82 schizophrenic patients by the double blind method]. ( Asada, S; Ishimaru, T; Kodama, H; Kubo, S; Masuda, K, 1976)
"Schizophrenia is a mental illness causing disordered beliefs, ideas and sensations."	2.50	Cannabis and schizophrenia. ( Gillies, D; Kalakouti, E; Kyprianou, K; McLoughlin, BC; Pushpa-Rajah, JA; Rathbone, J; Variend, H, 2014)
" anticholinergics and antiparkinsonian agents) until the effective dosage has been reached."	2.44	Practical issues with amisulpride in the management of patients with schizophrenia. ( Alptekin, K; Kontaxakis, VP; Pani, L; Villagrán, JM, 2008)
"Tardive Tourette syndrome is an extrapyramidal symptom which appears after long-term neuroleptic use."	2.43	[Two cases of tardive Tourette syndrome]. ( Ohmori, T; Yamauchi, K, 2006)
" It includes concepts of human neurobiology and neuropharmacology and their application to clinical medicine, as well as the presentation of the clinical evidence on the therapeutic efficacy and safety of amisulpride in schizophrenia, highlighting dosage issues."	2.41	Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia. ( Kasper, S, 2002)
" Safety was monitored by open adverse event reporting, the Simpson-Angus Scale, the Barnes Akathisia Scale and the Abnormal Involuntary Movement scale."	2.41	Safety profile of amisulpride in short- and long-term use. ( Coulouvrat, C; Dondey-Nouvel, L; Rein, W, 2000)
"In the long term treatment of schizophrenia, amisulpride maintained antipsychotic efficacy over a 12-month period in an open randomized study."	2.41	Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation? ( Blin, O, 2000)
" In patients with acute exacerbations of schizophrenia, the recommended dosage of amisulpride is 400 to 800 mg/day, although dosages < or =1200 mg/day may be administered."	2.41	Amisulpride: a review of its use in the management of schizophrenia. ( Curran, MP; Perry, CM, 2001)
"Schizophrenia is associated with significant social, psychological and occupational dysfunction."	2.41	Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride. ( Loo, H; Olié, JP; Saleem, P, 2002)
" In patients with acute exacerbations of schizophrenia, the recommended dosage of amisulpride is 400 to 800 mg/day, although dosages < or = 1200 mg/day may be administered."	2.41	Spotlight on amisulpride in schizophrenia. ( Curran, MP; Perry, CM, 2002)
"It appears to be an effective agent in treating schizophrenia for what are characterised as positive and negative symptoms."	2.41	Focus on amisulpride. ( Green, B, 2002)
" Safety data collection was performed using open reporting, UKU scales or specific extrapyramidal side-effect scales; electrocardiogram recording and vital signs examination; laboratory data collection."	2.40	Safety of amisulpride (Solian): a review of 11 clinical studies. ( Coulouvrat, C; Dondey-Nouvel, L, 1999)
"Sulpiride is a substituted benzamide with a selective action on receptors of the dopamine D2-like family, and clinical and pharmacological data suggest that it could be considered to be an atypical antipsychotic."	2.39	A risk-benefit assessment of sulpiride in the treatment of schizophrenia. ( Bitetto, A; Bravin, S; Invernizzi, G; Mauri, MC; Rudelli, R, 1996)
"The pharmacological treatment of schizophrenia is often performed with the simultaneous use of two or more antipsychotic agents to achieve the desired control of psychotic symptoms Available AP include both conventional (typical) and new (atypical) antipsychotic medications."	1.56	Identification and Quantification of Antipsychotics in Blood Samples by LC-MS-MS: Case Reports and Data from Three Years of Routine Analysis. ( Claro, A; Corte-Real, F; Franco, J; Monteiro, C; Mustra, C; Proença, P, 2020)
"Six weeks of individually dosed amisulpride treatment."	1.43	Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment. ( Ebdrup, BH; Glenthøj, B; Nielsen, MØ; Rostrup, E; Wulff, S, 2016)
"Aripiprazole is a first or second line treatment frequently used because it has reduced side effects such as weight gain, sleepiness, dyslipidemia, insulin resistance, hyperprolactinemia and extrapyramidal symptoms."	1.43	[Aripiprazole, gambling disorder and compulsive sexuality]. ( Dafreville, C; Mété, D; Paitel, V; Wind, P, 2016)
"A shorter duration of untreated psychosis has been associated with better prognosis in schizophrenia."	1.39	Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state. ( Higuchi, Y; Kawasaki, Y; Miyanishi, T; Seo, T; Sumiyoshi, T; Suzuki, M, 2013)
"Amisulpride is used for the treatment of schizophrenia and part of its safety profile is that is has no effect on the QT interval in therapeutic doses."	1.36	Amisulpride overdose: suggested management of prolonged QTc. ( Stevenson, RJ, 2010)
" Hitherto under-recognised toxic effects of novel chemotherapeutic agents can pose challenges for the forensic pathologist charged with performing medico-legal autopsies in cases of sudden unexpected death in young adults and particularly in those with schizophrenia."	1.35	Fatality due to amisulpride toxicity: a case report. ( George, N; Gerostamoulos, D; Lynch, MJ; Woods, J, 2008)
"Antipsychotic drugs are the mainstay of treatment in schizophrenia."	1.35	Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases. ( Akkaya, C; Ersoy, C; Kaya, B; Kirli, S; Kotan, Z; Sarandol, A, 2009)
"Schizophrenia is a severe mental disorder that requires lifelong treatment, and therefore information on the cardiovascular safety and tolerance of antipsychotics is of significant clinical importance."	1.35	Heart rate variability in schizophrenic patients switched from typical antipsychotic agents to amisulpride and olanzapine. 3-month follow-up. ( Bai, YM; Kuo, TB; Wang, YC; Yang, CC, 2008)
"Although schizophrenia affects all age groups, late or very-late-onset schizophrenia-like psychosis has not been well studied and various treatment issues remain unresolved."	1.35	Amisulpride for the treatment of very-late-onset schizophrenia-like psychosis. ( Papadimitriou, GN; Paparrigopoulos, TJ; Politis, AM; Psarros, C; Theleritis, CG, 2009)
" Preclinical evidence shows that chronic administration of antipsychotics can cause pituitary adenomas in female mice."	1.34	Atypical antipsychotics and pituitary neoplasms in the WHO database. ( Doraiswamy, PM; Edwards, R; Mueller-Oerlinghausen, B; Schott, G; Star, K, 2007)
"Risperidone monotherapy treatment was associated with hyperprolactinaemia in 69% of patients ( n = 35) and in 100% of female patients (n = 16) and amisulpride monotherapy in 100% (n = 7)."	1.34	Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. ( Bushe, C; Shaw, M, 2007)
"One patient died of pulmonary edema and subsequent heart failure, but the rest of the patients recovered without any sequelae."	1.34	Hemoperfusion in the treatment of acute clozapine intoxication in China. ( Cai, ZJ; He, JL; Li, WB; Ungvari, GS; Xiang, YT, 2007)
"Hypersalivation is a common, troublesome side effect of clozapine treatment."	1.33	Sulpiride addition for the treatment of clozapine-induced hypersalivation: preliminary study. ( Epshtein, S; Kreinin, A; Sheinkman, A; Tell, E, 2005)
"The galactorrhea is one of the possible side effects of psychotropic drugs."	1.33	[Endocrine side effects among psychiatric patients treated with antipsychotics]. ( Kovács, G; Kovács, L, 2006)
"Treatment with olanzapine was also associated with a higher frequency of remission compared with other antipsychotic agents."	1.33	Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. ( Alonso, J; Haro, JM; Lépine, JP; Novick, D; Ratcliffe, M; Suarez, D, 2006)
" However, no correlation between prolactin levels and dosage could be found."	1.32	[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics]. ( Fric, M; Laux, G, 2003)
" This allows the dosage to be adjusted and the treatment tailored to various clinical situations."	1.32	Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study. ( Linden, M; Scheel, T; Xaver Eich, F, 2004)
"The acute phase of schizophrenia is characterized by the presence of positive, negative and affective symptoms."	1.31	Acute phase of schizophrenia: impact of atypical antipsychotics. ( Azorin, JM, 2000)
"Susceptibility for malignant hyperthermia was detected by a positive in vitro contracture test."	1.31	[Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy]. ( Grohmann, R; Pedrosa Gil, F; Rüther, E; Schneider, C, 2001)
" No significant differences between young/adult and elderly patients for the various pharmacokinetic parameters (t1/2, AUC, Cmax, Tmax, Vd and Cl), after acute and multiple dosing, were observed."	1.29	L-sulpiride in young and elderly negative schizophrenics: clinical and pharmacokinetic variables. ( Altamura, CA; Coppola, MT; Leva, P; Mauri, MC, 1994)
"The sulpiride group had lower metabolic rates than the controls and the schizophrenic patients later treated with chlorpromazine."	1.28	Effects of sulpiride and chlorpromazine on regional cerebral glucose metabolism in schizophrenic patients as determined by positron emission tomography. ( Blomqvist, G; Greitz, T; Sjögren, I; Stone-Elander, S; Wiesel, FA; Wik, G, 1989)
"Sulpiride is a substituted benzamide which blocks selectively D-2 receptors."	1.28	[Sulpiride in psychiatric practice]. ( Faltus, F; Jirák, R; Pavlovský, P, 1989)
"Sulpiride is a neuroleptic drug which is believed to block especially the non-adenylate cyclase dopaminergic receptors which are supposed to be inhibitory axoaxonic receptors on glutamatergic corticostriatal terminals."	1.27	Cerebral glutamate, neuroleptic drugs and schizophrenia: increase of cerebrospinal fluid glutamate levels and decrease of striate body glutamate levels following sulpiride treatment in rats. ( Claus, D; Kim, JS; Kornhuber, HH, 1983)
" Whether this bipolar activity is due to the play of different kinds of receptors according to the dosage used, or is due to the dopaminergic blockade in different brain areas related to the dosage remains a problem to be solved."	1.27	[Efficacy of low doses of atypical neuroleptics (benzamides) in defect states]. ( Boyer, P, 1986)
"In a sulpiride-treated patient, the dosage was reduced in four steps over a nine-week period and a curvilinear relationship was demonstrated between central D2-dopamine receptor occupancy and serum drug concentrations."	1.27	Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. ( Farde, L; Halldin, C; Sedvall, G; Wiesel, FA, 1988)
"Sulpiride was also measured in cerebrospinal fluid from five drug-treated psychotic patients."	1.26	Quantitative analysis of sulpiride in body fluids by high-performance liquid chromatography with fluorescence detection. ( Alfredsson, G; Sedvall, G; Wiesel, FA, 1979)

Research

Studies (403)

Authors

Clinical Trials (12)

Trial Overview

Trial Outcomes

Change in Cognition

Timeframe	Studies, this research(%)	All Research%
pre-1990	67 (16.63)	18.7374
1990's	43 (10.67)	18.2507
2000's	172 (42.68)	29.6817
2010's	113 (28.04)	24.3611
2020's	8 (1.99)	2.80

Authors	Studies
Prljača, E	1
Bećirović, E	1
Hasanović, M	1
Pajević, I	1
Brigić, A	1
Zhu, MH	1
Liu, ZJ	1
Hu, QY	1
Yang, JY	1
Jin, Y	1
Zhu, N	1
Huang, Y	1
Shi, DH	1
Liu, MJ	1
Tan, HY	1
Zhao, L	1
Lv, QY	1
Yi, ZH	1
Wu, FC	1
Li, ZZ	1
Yang, S	1
Wang, H	1
Zheng, GF	1
Wang, Y	2
Li, L	2
Shang, DW	1
Wen, YG	1
Ning, YP	1
Proença, P	1
Monteiro, C	1
Mustra, C	1
Claro, A	1
Franco, J	1
Corte-Real, F	1
Wang, G	1
Zhou, B	1
Zheng, L	1
Ni, Y	1
Pan, A	1
Sun, F	1
Yu, F	1
Gao, Z	1
Ren, Z	1
Jin, W	1
Kang, SG	3
Chee, IS	3
Lee, K	3
Lee, J	3
Barber, S	1
Olotu, U	1
Corsi, M	1
Cipriani, A	3
Bak, N	2
Ebdrup, BH	3
Oranje, B	3
Fagerlund, B	1
Jensen, MH	1
Düring, SW	1
Nielsen, MØ	4
Glenthøj, BY	4
Hansen, LK	1
Hsu, CW	1
Lee, SY	1
Wang, LJ	1
Andrade, C	3
Barnes, TR	2
Leeson, VC	1
Paton, C	1
Marston, L	1
Davies, L	1
Whittaker, W	1
Osborn, D	1
Kumar, R	1
Keown, P	1
Zafar, R	1
Iqbal, K	1
Singh, V	1
Fridrich, P	1
Fitzgerald, Z	1
Bagalkote, H	1
Haddad, PM	1
Husni, M	1
Amos, T	1
Chang, HS	1
Na, KS	2
Gao, LJ	1
Guo, HG	1
Liang, ZT	1
Zhong, XX	1
Zhu, JC	1
Yang, Y	1
Kecel-Gunduz, S	1
Budama-Kilinc, Y	1
Cakir-Koc, R	1
Zorlu, T	1
Bicak, B	1
Kokcu, Y	1
Kaya, Z	1
Ozel, AE	1
Akyuz, S	1
Chang, CK	1
Hung, GC	2
Wang, Q	1
Cheung, C	1
Deng, W	1
Li, M	1
Huang, C	1
Ma, X	1
Jiang, L	1
Sham, PC	1
Collier, DA	1
Gong, Q	1
Chua, SE	1
McAlonan, GM	1
Li, T	1
Takács, R	1
Iványi, Z	1
Ungvari, GS	2
Gazdag, G	1
Vetlugina, TP	2
Lobacheva, OA	2
Al'perina, EL	2
Zhukova, EN	2
Semke, AV	1
Nikitina, VB	1
Cheĭdo, MA	2
Idova, GV	2
Nikiforuk, A	2
Kos, T	1
Fijał, K	1
Hołuj, M	2
Rafa, D	1
Popik, P	2
Lin, CH	1
Wang, FC	1
Lin, SC	1
Huang, YH	1
Chen, CC	4
Lane, HY	1
Kalkavoura, CS	1
Michopoulos, I	1
Arvanitakis, P	1
Theodoropoulou, P	1
Dimopoulou, K	1
Tzebelikos, E	1
Lykouras, L	3
Norlelawati, AT	1
Kartini, A	1
Norsidah, K	1
Ramli, M	1
Wan Azizi, WS	1
Tariq, AR	1
Meniavtseva, TA	1
Grassi, G	1
Poli, L	1
Cantisani, A	1
Righi, L	1
Ferrari, G	1
Pallanti, S	1
Volavka, J	2
Czobor, P	2
Citrome, L	1
Van Dorn, RA	1
Hotham, JE	1
Simpson, PJ	1
Brooman-White, RS	1
Basu, A	1
Ross, CC	1
Humphreys, SA	1
Larkin, F	1
Gupta, N	1
Das, M	1
Rafrafi, R	1
Abdelaghaffar, W	1
Ouanes, S	1
Bekri, I	1
Melki, W	1
El Hechmi, Z	1
Lai, EC	2
Hsieh, CY	1
Kao Yang, YH	2
Lin, SJ	2
Wang, J	4
Sampson, S	2
Wang, M	1
Hou, R	1
Jian, J	1
Mi, G	1
Qiu, H	1
Cao, B	1
Tang, M	2
Levine, SZ	5
Leucht, S	18
Düring, S	2
Andersen, GS	1
Cheng, CM	1
Tsai, SJ	2
Schirmbeck, F	2
Mier, D	1
Esslinger, C	2
Rausch, F	2
Englisch, S	3
Eifler, S	1
Meyer-Lindenberg, A	5
Kirsch, P	1
Zink, M	5
Pridan, S	1
Baruch, Y	1
Swartz, M	1
Barak, Y	1
McLoughlin, BC	1
Pushpa-Rajah, JA	1
Gillies, D	1
Rathbone, J	1
Variend, H	1
Kalakouti, E	1
Kyprianou, K	1
Porcelli, S	1
Serretti, A	1
Bianchini, O	1
Furukawa, TA	1
Tanaka, S	1
Goldberg, Y	1
Samara, M	1
Davis, JM	3
Toledo-Romero, F	2
Molina, JD	3
López-Rodríguez, E	2
Amorin-Díaz, M	2
Muñoz Algar, MJ	1
Aparicio-Castro, E	1
Chuang, WC	1
Chen, CY	3
Kuo, SC	3
Chen, TY	1
Yeh, YW	3
Dimitrakopoulou, V	1
Efthimiou, O	1
Salanti, G	1
Lee, HJ	1
Wulff, S	2
Pinborg, LH	1
Svarer, C	1
Jensen, LT	1
Allerup, P	1
Rasmussen, H	1
Frandsen, E	1
Rostrup, E	3
Winter-van Rossum, I	1
Heres, S	1
Arango, C	1
Fleischhacker, WW	8
Glenthøj, B	3
Leboyer, M	1
Leweke, FM	3
Lewis, S	1
McGuire, P	1
Rujescu, D	1
Kapur, S	5
Kahn, RS	5
Sommer, IE	2
Laoutidis, ZG	1
Konstantinidis, A	1
Grohmann, R	2
Luckhaus, C	1
Mobascher, J	1
Cordes, J	1
Tracy, DK	1
Joyce, DW	1
Sarkar, SN	1
Mateos Fernandez, MJ	1
Shergill, SS	1
Liang, Y	2
Su, YA	1
Zhao, ZG	1
Gao, N	1
Huang, JZ	1
Tang, MQ	1
Li, KQ	1
Yang, FD	1
Yu, X	2
Si, TM	1
Lee, CP	1
Chen, PJ	1
Chang, CM	1
Rogdaki, M	1
Jauhar, S	1
McCutcheon, R	1
Howes, O	1
Raghava, JM	1
Ho, PS	1
Liang, CS	1
Yen, CH	1
Lu, RB	1
Huang, SY	2
Marques, TR	1
Mété, D	1
Dafreville, C	1
Paitel, V	1
Wind, P	1
Hema, T	1
Maran, S	1
Subhashini, G	1
Sinha, P	1
Garg, A	1
Karbownik, MS	1
Szemraj, J	1
Wieteska, Ł	1
Antczak, A	1
Górski, P	1
Kowalczyk, E	1
Pietras, T	1
Cao, C	1
Zhu, C	1
Wang, C	1
Zhang, C	1
Dong, F	1
Yang, F	1
Deng, H	1
Yu, J	1
Tang, J	1
Su, L	1
Xin, L	1
Hong, L	1
Gao, M	1
Xie, S	1
Lu, S	1
Liu, T	1
Xu, X	1
Wang, X	2
Li, X	1
Li, Y	1
Zhang, Y	1
Chen, Z	1
Su, CH	1
Chen, CS	1
Huang, MF	1
Chen, WH	1
Huang, WL	1
Hsieh, MH	1
Sampford, JR	1
Li, BG	1
Zhao, S	1
Xia, J	1
Furtado, VA	1
Bas, A	1
Gultekin, G	1
Incir, S	1
Bas, TO	1
Emul, M	1
Duran, A	1
Chan, HY	1
Pan, YJ	1
Chen, JJ	1
Chen, CH	3
Lynch, MJ	1
Woods, J	1
George, N	1
Gerostamoulos, D	1
Akkaya, C	1
Kaya, B	1
Kotan, Z	1
Sarandol, A	1
Ersoy, C	1
Kirli, S	1
Müller, MJ	6
Eich, FX	9
Regenbogen, B	3
Sachse, J	2
Härtter, S	5
Hiemke, C	7
Chen, HK	1
Chen, CK	3
Tzeng, NS	1
Pani, L	4
Villagrán, JM	1
Kontaxakis, VP	2
Alptekin, K	1
Mendhekar, DN	2
Yajuvendra, B	1
Aggarwal, A	1
Chee, KY	1
Wang, YC	1
Yang, CC	1
Bai, YM	1
Kuo, TB	1
Baier, PC	1
Koch, JM	1
Seeck-Hirschner, M	1
Ohlmeyer, K	1
Wilms, S	1
Aldenhoff, JB	2
Hinze-Selch, D	1
Meisenzahl, EM	1
Schmitt, G	2
Gründer, G	5
Dresel, S	2
Frodl, T	2
la Fougère, C	2
Scheuerecker, J	1
Schwarz, M	1
Boerner, R	1
Stauss, J	2
Hahn, K	2
Möller, HJ	13
Lu, ML	2
Shen, WW	2
Riedel, M	2
Psarros, C	1
Theleritis, CG	2
Paparrigopoulos, TJ	1
Politis, AM	1
Papadimitriou, GN	3
Harangozó, J	2
Slezák, A	2
Borsos, K	2
Németh, O	2
Csukly, G	1
Chen, CL	1
Tschoner, A	1
Engl, J	1
Rettenbacher, MA	4
Kaser, S	1
Ott, HW	1
Patsch, JR	1
Ebenbichler, CF	1
Varol Tas, F	1
Guvenir, T	1
Omori, IM	3
Barceló, B	1
Yates, C	1
Castanyer, B	1
Puiguriguer, J	1
Goldberg, TE	1
Gomar, JJ	1
Ahn, YM	5
Lee, KY	3
Kim, CE	2
Kim, JJ	1
Kang, DY	2
Jun, TY	2
Choi, JS	1
Chung, IW	2
Kim, SH	4
Hwang, SS	3
Kim, YS	5
Chang, JS	2
Ravanić, DB	1
Pantović, MM	1
Milovanović, DR	1
Dukić-Dejanović, S	1
Janjić, V	1
Ignjatović, DR	1
Jović, SD	1
Jurisić, V	1
Jevtović, I	1
Sparshatt, A	1
Taylor, D	1
Patel, MX	1
Boso, M	1
Barbui, C	1
Kumar, A	1
Strech, D	1
Komossa, K	5
Rummel-Kluge, C	5
Hunger, H	5
Schwarz, S	5
Bhoopathi, PS	1
Kissling, W	8
Lambert, M	2
Schimmelmann, BG	2
Naber, D	5
Schulz, H	1
Huber, CG	1
Karow, A	1
Bhowmick, S	1
Hazra, A	1
Ghosh, M	1
Fenton, M	3
Soares, B	2
Jung, DC	2
Schmid, F	4
Silveira da Mota Neto, JI	1
Nuss, P	2
Tessier, C	1
Hoyer, C	2
Kranaster, L	1
Klosterkötter, J	3
Koethe, D	2
Gaebel, W	3
Riesbeck, M	1
von Wilmsdorff, M	1
Burns, T	2
Derks, EM	2
Rössler, W	1
Rizos, EN	1
Papadopoulou, A	1
Laskos, E	1
Michalopoulou, PG	1
Kastania, A	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy[NCT03652974]	Phase 4	145 participants (Actual)	Interventional	2018-09-06	Completed
A Randomized, Double-blind, Comparison of the Efficacy and Safety of Olanzapine Versus Low-dose Olanzapine Plus Low-dose Trifluoperazine in the Treatment of Schizophrenia[NCT02704962]	Phase 4	94 participants (Actual)	Interventional	2012-01-31	Completed
[NCT01615185]	Phase 4	96 participants (Actual)	Interventional	2008-01-31	Terminated
A Randomized Controlled Trial of Adjunctive Siltuximab in Schizophrenia[NCT02796859]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2016-05-31	Recruiting
An Open-Label Trial of Tocilizumab in Schizophrenia[NCT01696929]	Phase 1	8 participants (Actual)	Interventional	2012-09-30	Completed
Efficacy and Safety of Add-on Topiramate vs Metformin on Cardio-Metabolic Profile in Patients With Schizophrenia on Atypical Antipsychotics With Metabolic Syndrome: a Randomized Controlled Trial[NCT05663749]	Phase 4	60 participants (Actual)	Interventional	2022-09-20	Completed
Comparison of Benzamide Derivates (Amisulpride, Moclobemide and Tiapride) as Treatment of Clozapine-induced Hypersalivation: Pilot Double Phase Study: Open and Double-blind[NCT00534573]	Phase 3	54 participants (Actual)	Interventional	2008-11-30	Completed
Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia: A Randomised Placebo-controlled Double-blind Trial[NCT02533232]	Phase 1	60 participants (Anticipated)	Interventional	2022-08-30	Recruiting
Effectiveness of the RemedRugby Program, a Program of Ecological Cognitive Remediation of Social Cognition Disorders in Schizophrenia[NCT03775564]		60 participants (Actual)	Interventional	2014-11-30	Completed
"Interventional Triple-negative Placebo-controlled Personalized Prospective Study Evaluation of the Efficacy and Safety of Noninvasive Neuromodulation of TMS in Subjects With Catatonia"[NCT06176456]		60 participants (Anticipated)	Interventional	2023-11-01	Recruiting
1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700]	Phase 4	14 participants (Actual)	Interventional	2013-07-31	Terminated (stopped due to very slow recruitment, no sufficient results)
Sulpiride Versus Placebo for Reducting Hot Flushes During Climacteric: a Double-blind Randomized Clinical Trial[NCT02749747]	Phase 3	28 participants (Actual)	Interventional	2014-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The Brief Assessment of Cognition in Schizophrenia (BACS) is the metric used to characterize cognition in this study. The BACS consists of 6 subscales: Verbal Memory (range 0-75), Working Memory (range 0-28), Motor Speed (range 0-100), Verbal Fluency (measure is total number of words generated in two 60 second trials), Attention and Processing speed (range 0-110), and Executive Function (range 0-22). For each subscale, higher scores reflect better cognition. For each subscale, a Standard Deviation Score was calculated based on normative data (Keefe et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophrenia Research 102 (2008) 108-115). The BACS composite score is calculated as the average Standard Deviation Score of the 6 subscale scores. The change in BACS composite score was calculated as the BACS composite score at 8 weeks minus the BACS composite score at baseline. (NCT01696929)
Timeframe: Change in BACS composite score from baseline to 8 weeks

Change in Total Psychotic Symptoms

Intervention	Change in BACS Composite Score (Mean)
Tocilizumab	0.7

The Positive and Negative Symptoms Scale (PANSS) is the metric used to characterize psychotic symptoms in this study. The PANSS consists of 30 items, each scored 1-7. The range for the PANSS total score is 30-210. There are 3 subscales - PANSS positive score (range 7-49), PANSS negative score (range 7-49), and PANSS general score (range 16-112). PANSS total score is the summation of these 3 subscales. Higher values for the total and subscale scores reflect more severe psychopathology. A positive change in PANSS total score reflects an increase in psychopathology. A negative change in PANSS total score reflects a decrease in psychopathology. (NCT01696929)
Timeframe: Change in PANSS total score from baseline to 8 weeks

Intervention	percentage of weight change (Mean)
Ziprasidone	11.58
Aripiprazole, Quetiapine, Risperidone	5.66

Intervention	BMI z-score (Mean)
	baseline	week 12 (n=1, n=2)
Aripiprazole, Quetiapine, Risperidone	-0.37	0.38
Ziprasidone	-0.51	0.22

Intervention	lbs (Mean)
	baseline	week 12 (n=1,2)
Aripiprazole, Quetiapine, Risperidone	118.5	141
Ziprasidone	120.5	151

Article	Year
Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. Military Medical Research, 2022, 10-18, Volume: 9, Issue:1 Topics: Amisulpride; Antipsychotic Agents; Clozapine; Cognition; Humans; Schizophrenia; Schizophrenia, Treat	2022
rs7968606 polymorphism of ANKS1B is associated with improvement in the PANSS general score of schizophrenia caused by amisulpride. Human psychopharmacology, 2017, Volume: 32, Issue:2 Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Carrier Proteins; Double-Blind Method; F	2017
Two subgroups of antipsychotic-naive, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology. Translational psychiatry, 2017, 04-11, Volume: 7, Issue:4 Topics: Adult; Algorithms; Amisulpride; Antipsychotic Agents; Cognition Disorders; Electroencephalography; E	2017
Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. Health technology assessment (Winchester, England), 2017, Volume: 21, Issue:49 Topics: Adult; Amisulpride; Antipsychotic Agents; Clozapine; Cost-Benefit Analysis; Double-Blind Method; Dru	2017
Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study. International clinical psychopharmacology, 2013, Volume: 28, Issue:5 Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Cost Savings; Diagnostic and Statistical Ma	2013
Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study. International clinical psychopharmacology, 2013, Volume: 28, Issue:5 Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Cost Savings; Diagnostic and Statistical Ma	2013
Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study. International clinical psychopharmacology, 2013, Volume: 28, Issue:5 Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Cost Savings; Diagnostic and Statistical Ma	2013
Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study. International clinical psychopharmacology, 2013, Volume: 28, Issue:5 Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Cost Savings; Diagnostic and Statistical Ma	2013
Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. CNS spectrums, 2014, Volume: 19, Issue:5 Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Hostilit	2014
Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials. Schizophrenia research, 2014, Volume: 156, Issue:1 Topics: Adult; Amisulpride; Antipsychotic Agents; Double-Blind Method; Female; Follow-Up Studies; Humans; Ma	2014
Acute Effects of Haloperidol, Amisulpride, and Quetiapine on Bone Turnover Markers in Patients With Schizophrenia. Journal of clinical psychopharmacology, 2015, Volume: 35, Issue:5 Topics: Adult; Amisulpride; Antipsychotic Agents; Biomarkers; Bone Remodeling; Bone Resorption; Female; Halo	2015
The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8-week, prospective, open-label, multicenter, single-arm study. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists, 2016, Volume: 8, Issue:3 Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Prospective	2016
Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. Journal of psychopharmacology (Oxford, England), 2009, Volume: 23, Issue:3 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Comorbid	2009
Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study. Pharmacopsychiatry, 2008, Volume: 41, Issue:5 Topics: Adult; Amisulpride; Antipsychotic Agents; Benzamides; Corpus Striatum; Dose-Response Relationship, D	2008
Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Progress in neuro-psychopharmacology & biological psychiatry, 2008, Dec-12, Volume: 32, Issue:8 Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Cross-Over Studies; Dru	2008
A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients. European psychiatry : the journal of the Association of European Psychiatrists, 2009, Volume: 24, Issue:3 Topics: Age Factors; Aged; Amisulpride; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Di	2009
Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls. Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:2 Topics: Adult; Amisulpride; Antipsychotic Agents; Cognition Disorders; Female; Follow-Up Studies; Humans; Ma	2009
Long-term efficacy of electroconvulsive therapy combined with different antipsychotic drugs in previously resistant schizophrenia. Psychiatria Danubina, 2009, Volume: 21, Issue:2 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Combined Modality Therapy; Dose-Response Relationship,	2009
Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. Pharmacopsychiatry, 2009, Volume: 42, Issue:6 Topics: Adult; Amisulpride; Antipsychotic Agents; Cohort Studies; Female; Humans; Linear Models; Male; Progn	2009
Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial. The Australian and New Zealand journal of psychiatry, 2010, Volume: 44, Issue:3 Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Drug Admi	2010
Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2010, Volume: 20, Issue:5 Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperidol;	2010
Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophrenia research, 2010, Volume: 121, Issue:1-3 Topics: Adult; Amisulpride; Celecoxib; Cyclooxygenase 2 Inhibitors; Dopamine Antagonists; Dose-Response Rela	2010
Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophrenia research, 2010, Volume: 121, Issue:1-3 Topics: Adult; Amisulpride; Celecoxib; Cyclooxygenase 2 Inhibitors; Dopamine Antagonists; Dose-Response Rela	2010
Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophrenia research, 2010, Volume: 121, Issue:1-3 Topics: Adult; Amisulpride; Celecoxib; Cyclooxygenase 2 Inhibitors; Dopamine Antagonists; Dose-Response Rela	2010
Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophrenia research, 2010, Volume: 121, Issue:1-3 Topics: Adult; Amisulpride; Celecoxib; Cyclooxygenase 2 Inhibitors; Dopamine Antagonists; Dose-Response Rela	2010
Amisulpride versus moclobemide in treatment of clozapine-induced hypersalivation. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2011, Volume: 12, Issue:8 Topics: Adult; Aged; Amisulpride; Antipsychotic Agents; Clozapine; Cross-Over Studies; Female; Humans; Male;	2011
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). The Journal of clinical psychiatry, 2011, Volume: 72, Issue:7 Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Haloperid	2011
The acute and long-term effectiveness of amisulpride in patients with schizophrenia: results of a 12-month open-label prospective follow-up study. Human psychopharmacology, 2011, Volume: 26, Issue:8 Topics: Adult; Amisulpride; Antipsychotic Agents; Female; Follow-Up Studies; Humans; Male; Prospective Studi	2011
Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride. Pharmacopsychiatry, 2012, Volume: 45, Issue:2 Topics: Adult; Amisulpride; Antipsychotic Agents; Drug Tolerance; Female; Humans; Hyperprolactinemia; Male;	2012
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2013, Volume: 23, Issue:3 Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dibenzot	2013
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational psychiatry, 2012, Mar-20, Volume: 2 Topics: Acute Disease; Adult; Amides; Amisulpride; Antipsychotic Agents; Arachidonic Acids; Cannabidiol; Dou	2012
A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia. Clinical drug investigation, 2012, Volume: 32, Issue:11 Topics: Adult; Aged; Amisulpride; Analysis of Variance; Antipsychotic Agents; Chi-Square Distribution; Disea	2012
Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms. Schizophrenia research, 2013, Volume: 145, Issue:1-3 Topics: Amisulpride; Antipsychotic Agents; Double-Blind Method; Female; Humans; Intention; Male; Psychiatric	2013
Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: an evaluation using confirmatory factor analysis. International clinical psychopharmacology, 2002, Volume: 17, Issue:5 Topics: Adolescent; Adult; Affect; Aged; Amisulpride; Antipsychotic Agents; Double-Blind Method; Factor Anal	2002
Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology, 2002, Volume: 46, Issue:1 Topics: Adult; Amisulpride; Antipsychotic Agents; Drug Administration Schedule; Female; Flupenthixol; Humans	2002
A pilot cross-over design study on QTc interval prolongation associated with sulpiride and haloperidol. Schizophrenia research, 2003, Jan-01, Volume: 59, Issue:1 Topics: Adolescent; Adult; Antipsychotic Agents; Cross-Over Studies; Female; Haloperidol; Heart Conduction S	2003
A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. Current medical research and opinion, 2002, Volume: 18, Issue:6 Topics: Adolescent; Adult; Aged; Amisulpride; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; B	2002
Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia. Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:6 Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Halo	2002
Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2002, Volume: 27, Issue:6 Topics: Adolescent; Adult; Aged; Amisulpride; Analysis of Variance; Chi-Square Distribution; Chronic Disease	2002
Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan. Journal of the Formosan Medical Association = Taiwan yi zhi, 2003, Volume: 102, Issue:1 Topics: Amisulpride; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Pilot Projects; Psychi	2003
Plasma amisulpride levels in schizophrenia or schizoaffective disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2004, Volume: 14, Issue:3 Topics: Adolescent; Adult; Age Factors; Amisulpride; Antipsychotic Agents; Biomimetics; Chromatography, High	2004
A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. International clinical psychopharmacology, 2004, Volume: 19, Issue:2 Topics: Acute Disease; Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brief Ps	2004
Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. International clinical psychopharmacology, 2004, Volume: 19, Issue:1 Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Anxiety; Basal Ganglia Diseases; Benzodiazepines; C	2004
Clozapine with amisulpride for refractory schizophrenia. The American journal of psychiatry, 2004, Volume: 161, Issue:5 Topics: Adult; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Drug Therapy, C	2004
Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta psychiatrica Scandinavica, 2004, Volume: 110, Issue:4 Topics: Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Diagnostic and Statist	2004
Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2005, Volume: 30, Issue:2 Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Attention; Benzodiazepines; Cognition; D	2005
Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride. Psychopharmacology, 2005, Volume: 180, Issue:4 Topics: Adult; Amisulpride; Antipsychotic Agents; Benzamides; Binding, Competitive; Brain Mapping; Case-Cont	2005
Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study. Progress in neuro-psychopharmacology & biological psychiatry, 2005, Volume: 29, Issue:4 Topics: Adult; Amisulpride; Antipsychotic Agents; Cost of Illness; Cost-Benefit Analysis; Costs and Cost Ana	2005
The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study. BMC psychiatry, 2005, May-03, Volume: 5 Topics: Adult; Amisulpride; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Sche	2005
Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine. Biological psychiatry, 2006, Mar-15, Volume: 59, Issue:6 Topics: Acoustic Stimulation; Adult; Amisulpride; Antipsychotic Agents; Attention; Benzodiazepines; Dopamine	2006
Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. International clinical psychopharmacology, 2006, Volume: 21, Issue:2 Topics: Amisulpride; Antipsychotic Agents; Clozapine; Cross-Over Studies; Double-Blind Method; Female; Human	2006
Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. International clinical psychopharmacology, 2006, Volume: 21, Issue:3 Topics: Adult; Adverse Drug Reaction Reporting Systems; Amisulpride; Antipsychotic Agents; Behavioral Sympto	2006
Switching to amisulpride monotherapy for treatment-resistant schizophrenia. European psychiatry : the journal of the Association of European Psychiatrists, 2006, Volume: 21, Issue:3 Topics: Adult; Amisulpride; Antipsychotic Agents; Drug Resistance; Follow-Up Studies; Humans; Male; Psychiat	2006
Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. Pharmacopsychiatry, 2006, Volume: 39, Issue:2 Topics: Adult; Amisulpride; Antipsychotic Agents; Drug Administration Schedule; Drug Monitoring; Drug Tolera	2006
Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology, 2006, Volume: 186, Issue:4 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; C-Peptide; Cholesterol	2006
Early changes of plasma lipids during treatment with atypical antipsychotics. International clinical psychopharmacology, 2006, Volume: 21, Issue:6 Topics: Adolescent; Adult; Aged; Amisulpride; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; B	2006
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta psychiatrica Scandinavica, 2006, Volume: 114, Issue:5 Topics: Adult; Affect; Amisulpride; Antipsychotic Agents; Attention; Basal Ganglia Diseases; Benzodiazepines	2006
A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. European psychiatry : the journal of the Association of European Psychiatrists, 2006, Volume: 21, Issue:8 Topics: Adult; Amisulpride; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Comorbidity; Depres	2006
Delta power in sleep in relation to neuropsychological performance in healthy subjects and schizophrenia patients. The Journal of neuropsychiatry and clinical neurosciences, 2006,Fall, Volume: 18, Issue:4 Topics: Adult; Amisulpride; Antipsychotic Agents; Case-Control Studies; Delta Rhythm; Female; Fourier Analys	2006
Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta psychiatrica Scandinavica, 2007, Volume: 115, Issue:2 Topics: Adult; Amisulpride; Antipsychotic Agents; Female; Humans; International Classification of Diseases;	2007
A preliminary fMRI study of the effects on cortical activation of the treatment of refractory auditory hallucinations with rTMS. Psychiatry research, 2007, May-15, Volume: 155, Issue:1 Topics: Adult; Amisulpride; Antipsychotic Agents; Clozapine; Combined Modality Therapy; Female; Functional L	2007
Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. International clinical psychopharmacology, 2007, Volume: 22, Issue:3 Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weig	2007
Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia. Human psychopharmacology, 2007, Volume: 22, Issue:7 Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dose-	2007
Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. Progress in neuro-psychopharmacology & biological psychiatry, 2007, Oct-01, Volume: 31, Issue:7 Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Depressive Disorder; Electrocardiography; Endp	2007
Increase in plasma concentration of amisulpride after addition of concomitant lithium. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:5 Topics: Adult; Amisulpride; Antimanic Agents; Antipsychotic Agents; Borderline Personality Disorder; Chromat	2007
Two-year study of relapse prevention by a new education program in schizophrenic patients treated with the same antipsychotic drug. European psychiatry : the journal of the Association of European Psychiatrists, 2008, Volume: 23, Issue:1 Topics: Adult; Amisulpride; Antipsychotic Agents; Clinical Trials, Phase IV as Topic; Control Groups; Female	2008
Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. The British journal of psychiatry. Supplement, 2007, Volume: 51 Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Combined Modality Therapy; Drug Administration	2007
Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. Neuro endocrinology letters, 2007, Volume: 28, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibe	2007
Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry, 2008, Volume: 41, Issue:1 Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapin	2008
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet (London, England), 2008, Mar-29, Volume: 371, Issue:9618 Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; H	2008
Atypical neuroleptics: clozapine and the benzamides in the prevention and treatment of tardive dyskinesia. Modern problems of pharmacopsychiatry, 1983, Volume: 21 Topics: Antipsychotic Agents; Benzamides; Clinical Trials as Topic; Clozapine; Dibenzazepines; Dose-Response	1983
Amisulpride--an open clinical study of a new benzamide in schizophrenic patients. Pharmacopsychiatry, 1984, Volume: 17, Issue:4 Topics: Adult; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Electroe	1984
Relationships between drug concentrations in serum and CSF, clinical effects and monoaminergic variables in schizophrenic patients treated with sulpiride or chlorpromazine. Acta psychiatrica Scandinavica. Supplementum, 1984, Volume: 311 Topics: Adolescent; Adult; Chlorpromazine; Clinical Trials as Topic; Double-Blind Method; Female; Homovanill	1984
Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report. Acta psychiatrica Scandinavica. Supplementum, 1984, Volume: 311 Topics: Adult; Autonomic Nervous System; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol;	1984
Clinical evaluation of sulpiride in schizophrenic patients--a double-blind comparison with chlorpromazine. Acta psychiatrica Scandinavica. Supplementum, 1984, Volume: 311 Topics: Adolescent; Adult; Benzodiazepines; Chlorpromazine; Clinical Trials as Topic; Double-Blind Method; D	1984
Sulpiride trial in chronic schizophrenia with comparison of two dosage regimens. Psychopharmacology, 1983, Volume: 80, Issue:3 Topics: Adult; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Mid	1983
Effects of sulpiride and chlorpromazine on depressive symptoms in schizophrenic patients--relationship to drug concentrations. Psychopharmacology, 1984, Volume: 84, Issue:2 Topics: Adolescent; Adult; Basal Ganglia Diseases; Chlorpromazine; Depression; Female; Humans; Male; Schizop	1984
A clinical and pharmacodynamic evaluation of sulpiride. Psychopharmacology, 1981, Volume: 73, Issue:1 Topics: Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; Humans; Middle	1981
Controlled trial of sulpiride in chronic schizophrenic patients. The British journal of psychiatry : the journal of mental science, 1980, Volume: 137 Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Bli	1980
Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. The American journal of psychiatry, 1995, Volume: 152, Issue:1 Topics: Adult; Amisulpride; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Sched	1995
Neuroendocrine profile of SDZ HDC-912 and OPC-4392, two new atypical antipsychotic drugs, in schizophrenic patients. Psychopharmacology, 1993, Volume: 110, Issue:1-2 Topics: Adult; Amisulpride; Antipsychotic Agents; Apomorphine; Dopamine Agonists; Ergolines; Female; Growth	1993
Treatment of negative symptoms in schizophrenia with amisulpride. The British journal of psychiatry : the journal of mental science, 1995, Volume: 166, Issue:1 Topics: Adult; Amisulpride; Antipsychotic Agents; Depression; Dose-Response Relationship, Drug; Double-Blind	1995
Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine. Neuropsychobiology, 1994, Volume: 29, Issue:3 Topics: Adult; Amisulpride; Antipsychotic Agents; Arousal; Attention; Brain Mapping; Cerebral Cortex; Dose-R	1994
Energy metabolism in the hypothalamus and plasma cortisol levels in patients with schizophrenia. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1996, Volume: 28, Issue:4 Topics: Antipsychotic Agents; Chlorpromazine; Energy Metabolism; Glucose; Humans; Hydrocortisone; Hypothalam	1996
In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology, 1996, Volume: 124, Issue:1-2 Topics: Adult; Amisulpride; Brain; Female; Humans; Male; Receptors, Dopamine D2; Schizophrenia; Sulpiride; T	1996
Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. The British journal of psychiatry : the journal of mental science, 1997, Volume: 170 Topics: Adult; Akathisia, Drug-Induced; Amisulpride; Antiparkinson Agents; Antipsychotic Agents; Double-Blin	1997
Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology, 1997, Volume: 132, Issue:4 Topics: Adult; Akathisia, Drug-Induced; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; D	1997
One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. The British journal of psychiatry : the journal of mental science, 1997, Volume: 171 Topics: Adult; Aged; Amisulpride; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Humans	1997
Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. The British journal of psychiatry : the journal of mental science, 1997, Volume: 171 Topics: Adult; Antipsychotic Agents; Clozapine; Dopamine Antagonists; Double-Blind Method; Drug Synergism; D	1997
Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta psychiatrica Scandinavica, 1998, Volume: 98, Issue:1 Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Bl	1998
Neuroendocrine response to antipsychotics: effects of drug type and gender. Biological psychiatry, 1999, Jan-01, Volume: 45, Issue:1 Topics: Adult; Amisulpride; Antipsychotic Agents; Double-Blind Method; Female; Flupenthixol; Human Growth Ho	1999
Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. The American journal of psychiatry, 1999, Volume: 156, Issue:4 Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind	1999
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry research, 1999, Nov-08, Volume: 88, Issue:2 Topics: Acute Disease; Adult; Amisulpride; Antipsychotic Agents; Body Weight; Double-Blind Method; Female; H	1999
Quantitative EEG in schizophrenic patients before and during pharmacotherapy. Neuropsychobiology, 2000, Volume: 41, Issue:3 Topics: Adult; Antipsychotic Agents; Beta Rhythm; Delta Rhythm; Electroencephalography; Female; Fluphenazine	2000
Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. International clinical psychopharmacology, 2000, Volume: 15, Issue:1 Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Chronic Disease; Dyskinesia, Drug-Induce	2000
Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia. Journal of clinical psychopharmacology, 2000, Volume: 20, Issue:5 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Resistance; Drug Therapy, Combination; Female; Hu	2000
Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). European psychiatry : the journal of the Association of European Psychiatrists, 2000, Volume: 15, Issue:5 Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Double-Blind M	2000
Serum levels of sulpiride enantiomers after oral treatment with racemic sulpiride in psychiatric patients: a pilot study. Pharmacopsychiatry, 2001, Volume: 34, Issue:1 Topics: Adult; Antipsychotic Agents; Chromatography, High Pressure Liquid; Depressive Disorder; Female; Huma	2001
Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. European archives of psychiatry and clinical neuroscience, 2001, Volume: 251, Issue:3 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dopamine Antagonists; Dose-Response Relatio	2001
Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia. European archives of psychiatry and clinical neuroscience, 2001, Volume: 251, Issue:5 Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease;	2001
Sulpiride--an antipsychotic agent: comparative trial vs. haloperidol. Psychopharmacology bulletin, 1977, Volume: 13, Issue:3 Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female;	1977
An evaluation of a unique new antipsychotic agent, sulpiride: effects on serum prolactin and growth hormone levels. The American journal of psychiatry, 1977, Volume: 134, Issue:12 Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evalua	1977
[Comparative trials on sultopride and fluanisone]. L'Encephale, 1978, Volume: 4, Issue:2 Topics: Antipsychotic Agents; Bibliographies as Topic; Butyrophenones; Evaluation Studies as Topic; Female;	1978
Sulpiride: evaluation of antipsychotic activity in schizophrenic patients. Diseases of the nervous system, 1977, Volume: 38, Issue:7 Topics: Adult; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Middle Aged; Prolactin; Schi	1977
[Clinical studies with sulpiride in schizophrenics hospitalized for many years]. Agressologie: revue internationale de physio-biologie et de pharmacologie appliquees aux effets de l'agression, 1978, Volume: 19, Issue:C Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Schizophr	1978
[Therapeutic and side effects of treatment with sulpiride]. Agressologie: revue internationale de physio-biologie et de pharmacologie appliquees aux effets de l'agression, 1978, Volume: 19, Issue:C Topics: Adult; Clinical Trials as Topic; Female; Humans; Male; Mental Disorders; Middle Aged; Schizophrenia;	1978
Comparison of sulpiride and chlorpromazine in psychoses. A double-blind multicentre study. Acta psychiatrica Scandinavica, 1979, Volume: 60, Issue:1 Topics: Adult; Chlorpromazine; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Humans; Middl	1979
[Study of the clinical effects of sulpiride and perphenazine in 82 schizophrenic patients by the double blind method]. L'Encephale, 1976, Volume: 2, Issue:1 Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubin; Clinical	1976
The evaluation of the anti-autistic activity of sulpiride. Current therapeutic research, clinical and experimental, 1975, Volume: 18, Issue:4 Topics: Adolescent; Adult; Autistic Disorder; Clinical Trials as Topic; Female; Humans; Male; Placebos; Psyc	1975
Clinico-pharmacological studies of sulpiride. Current therapeutic research, clinical and experimental, 1976, Volume: 20, Issue:2 Topics: Adult; Clinical Trials as Topic; Depression; Female; Hallucinations; Humans; Male; Middle Aged; Schi	1976
[A new substituted benzamide with neuroleptic effects: lin 14 18 or sultopride]. L'Encephale, 1975, Volume: 1, Issue:1 Topics: Adult; Aged; Benzamides; Clinical Trials as Topic; Delusions; Drug Evaluation; Humans; Male; Middle	1975
[Situation of sultopride among present-day neuroleptics]. L'Encephale, 1975, Volume: 1, Issue:1 Topics: Anxiety; Asthenia; Basal Ganglia Diseases; Benzamides; Bipolar Disorder; Clinical Trials as Topic; D	1975
Efficacy of low vs. high doses of levosulpiride on negative symptoms of schizophrenia. Pharmacopsychiatry, 1992, Volume: 25, Issue:3 Topics: Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Schizophrenia; Schizophrenic Psycholo	1992
New antipsychotics: classification, efficacy, and adverse effects. Schizophrenia bulletin, 1991, Volume: 17, Issue:2 Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Humans; Isoxazoles; Piperidines; Receptors	1991
Treatment of positive and negative symptoms: pharmacologic approaches. Modern problems of pharmacopsychiatry, 1990, Volume: 24 Topics: Adult; Amisulpride; Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug	1990
Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study. Pharmacopsychiatry, 1990, Volume: 23, Issue:3 Topics: Adult; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female; Halop	1990
Sulpiride in tardive dyskinesia. Journal of neurology, neurosurgery, and psychiatry, 1990, Volume: 53, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Long	1990
[Results of treatment of schizophrenic and schizoaffective patients with sulpiride (Eglonyl Alkaloid) in comparison with perphenazine (Perfenazin Spofa)]. Ceskoslovenska psychiatrie, 1990, Volume: 86, Issue:3 Topics: Adolescent; Adult; Humans; Middle Aged; Perphenazine; Psychotic Disorders; Schizophrenia; Sulpiride	1990
Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenic patients. Psychopharmacology, 1990, Volume: 101, Issue:3 Topics: Adolescent; Adult; Amino Acids; Biogenic Monoamines; Female; Humans; Male; Psychiatric Status Rating	1990
Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology, 1989, Volume: 99, Issue:3 Topics: Adolescent; Adult; Amino Acids; Biogenic Monoamines; Female; Glutamates; Glutamine; Homovanillic Aci	1989
Dose finding and serum concentrations of neuroleptics in the treatment of schizophrenic patients. Psychopharmacology series, 1989, Volume: 7 Topics: Antipsychotic Agents; Double-Blind Method; Humans; Psychiatric Status Rating Scales; Randomized Cont	1989
Prophylactic effects of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of timiperone and sulpiride. Biological psychiatry, 1989, Apr-01, Volume: 25, Issue:7 Topics: Adult; Butyrophenones; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle A	1989
Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial. Acta psychiatrica Scandinavica, 1989, Volume: 80, Issue:1 Topics: Acute Disease; Adolescent; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Double-Blind Meth	1989
[Benzamides, a therapeutic response adapted to 2 sides, paranoid and hebephrenic, of schizophrenia]. Annales medico-psychologiques, 1985, Volume: 143, Issue:7 Topics: Amisulpride; Antipsychotic Agents; Benzamides; Clinical Trials as Topic; Double-Blind Method; Humans	1985
[Three antipsychotic drugs in the treatment of schizophrenia--a controlled and double-blind study]. Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry, 1988, Volume: 21, Issue:5 Topics: Adolescent; Adult; Chlorpromazine; Clinical Trials as Topic; Clozapine; Dibenzazepines; Double-Blind	1988
A single-blind study of clocapramine and sulpiride in hospitalized chronic schizophrenic patients. Drugs under experimental and clinical research, 1988, Volume: 14, Issue:11 Topics: Adult; Chronic Disease; Dibenzazepines; Female; Humans; Male; Middle Aged; Psychiatric Status Rating	1988
The effect of sulpiride on negative symptoms of schizophrenia. The British journal of psychiatry : the journal of mental science, 1987, Volume: 150 Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Male; Sch	1987
Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations. The British journal of psychiatry : the journal of mental science, 1985, Volume: 147 Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; Humans;	1985
Effects of sulpiride and chlorpromazine on autistic and positive psychotic symptoms in schizophrenic patients--relationship to drug concentrations. Psychopharmacology, 1985, Volume: 85, Issue:1 Topics: Adolescent; Adult; Autistic Disorder; Behavior; Chlorpromazine; Clinical Trials as Topic; Double-Bli	1985
[Long- and short-term effects of sulpiride on sleep-EEG of man]. Arzneimittel-Forschung, 1974, Volume: 24, Issue:7 Topics: Administration, Oral; Adult; Aged; Clinical Trials as Topic; Depression; Electroencephalography; Fem	1974
[Clinical studies of sulpride on long standing hospitalized schizophrenic patients]. Arzneimittel-Forschung, 1974, Volume: 24, Issue:7 Topics: Adult; Autistic Disorder; Catatonia; Clinical Trials as Topic; Depressive Disorder, Major; Drug Eval	1974
[Clinical-neuroleptic investigation of N-((1-ethyl-pyrrolidine-2-yl)-methyl)-2-methoxy-5-sulfamyl-benzamide-neuroleptic sulpiride (Dogmatil) in acutly ill schizophrenics]. International pharmacopsychiatry, 1974, Volume: 9, Issue:2 Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Biperiden; Blood Pressure; Clinical Trials as Topic	1974

sulpiride and Schizophrenia

Research Excerpts

Research

Studies (403)

Authors

Clinical Trials (12)

Trial Overview

Trial Outcomes

Change in Cognition

Change in Total Psychotic Symptoms

Percent Weight Change Compared to Baseline Weight

BMI Percentile

BMI Z-scores

Weight Change

Reviews

Trials

Other Studies

Article	Year
A systematic review and combined meta-analysis of concentration of oral amisulpride. British journal of clinical pharmacology, 2020, Volume: 86, Issue:4 Topics: Aged; Amisulpride; Antipsychotic Agents; Drug Monitoring; Female; Humans; Schizophrenia; Sulpiride	2020
Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. The Cochrane database of systematic reviews, 2017, 03-23, Volume: 3 Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Clozapine; Dibenzothiazepines; Drug Resistan	2017
Sulpiride versus placebo for schizophrenia. The Cochrane database of systematic reviews, 2014, Apr-11, Issue:4 Topics: Antipsychotic Agents; Humans; Placebos; Randomized Controlled Trials as Topic; Schizophrenia; Sulpir	2014
Cannabis and schizophrenia. The Cochrane database of systematic reviews, 2014, Oct-14, Issue:10 Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Cannabinoids; Humans; Marijuana Abuse; Medical M	2014
Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA psychiatry, 2015, Volume: 72, Issue:1 Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Drug Monitoring; Female; Humans; Male; Ol	2015
The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Schizophrenia bulletin, 2015, Volume: 41, Issue:3 Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clinical Trials	2015
Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. The Cochrane database of systematic reviews, 2016, Jul-02, Volume: 7 Topics: Administration, Oral; Amisulpride; Antipsychotic Agents; Benzodiazepines; Fluphenazine; Humans; Olan	2016
Practical issues with amisulpride in the management of patients with schizophrenia. Clinical drug investigation, 2008, Volume: 28, Issue:8 Topics: Amisulpride; Antipsychotic Agents; Drug Resistance; Drug Therapy, Combination; Humans; Schizophrenia	2008
Sulpiride versus placebo for schizophrenia. The Cochrane database of systematic reviews, 2009, Apr-15, Issue:2 Topics: Antipsychotic Agents; Humans; Placebos; Randomized Controlled Trials as Topic; Schizophrenia; Sulpir	2009
Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. Acta psychiatrica Scandinavica, 2009, Volume: 120, Issue:6 Topics: Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Drug Monitoring	2009
Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. The Cochrane database of systematic reviews, 2009, 07-08, Issue:3 Topics: Amisulpride; Antipsychotic Agents; Clozapine; Dibenzothiazepines; Drug Resistance; Drug Therapy, Com	2009
Zuclopenthixol dihydrochloride for schizophrenia. Schizophrenia bulletin, 2009, Volume: 35, Issue:5 Topics: Antipsychotic Agents; Clopenthixol; Dyskinesia, Drug-Induced; Humans; Randomized Controlled Trials a	2009
Ziprasidone versus other atypical antipsychotics for schizophrenia. The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4 Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapin	2009
Sulpiride augmentation for schizophrenia. Schizophrenia bulletin, 2010, Volume: 36, Issue:2 Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Humans; Long-Term Care; Randomized Contr	2010
Amisulpride versus other atypical antipsychotics for schizophrenia. The Cochrane database of systematic reviews, 2010, Jan-20, Issue:1 Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Piperazines; Randomized Cont	2010
Sulpiride augmentation for schizophrenia. The Cochrane database of systematic reviews, 2010, Jan-20, Issue:1 Topics: Antipsychotic Agents; Clozapine; Drug Synergism; Drug Therapy, Combination; Humans; Randomized Contr	2010
Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride. Current medical research and opinion, 2010, Volume: 26, Issue:4 Topics: Activities of Daily Living; Amisulpride; Antipsychotic Agents; Clinical Trials as Topic; Humans; Qua	2010
Olanzapine versus other atypical antipsychotics for schizophrenia. The Cochrane database of systematic reviews, 2010, Mar-17, Issue:3 Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Hum	2010
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophrenia research, 2010, Volume: 123, Issue:2-3 Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Clinic	2010
Risperidone versus other atypical antipsychotics for schizophrenia. The Cochrane database of systematic reviews, 2011, Jan-19, Issue:1 Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Hum	2011
Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophrenia bulletin, 2012, Volume: 38, Issue:5 Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Citalopram; Clozapine; Dioxoles; Double-Blind	2012
Delayed- and early-onset hypotheses of antipsychotic drug action in the negative symptoms of schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2012, Volume: 22, Issue:11 Topics: Amisulpride; Anhedonia; Antipsychotic Agents; Drug Resistance; Humans; Randomized Controlled Trials	2012
Clinical implications of dopamine research in schizophrenia. Current medical research and opinion, 2002, Volume: 18 Suppl 3 Topics: Amisulpride; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Humans; Receptors, Dopamine; Res	2002
Amisulpride: progress and outcomes. Current medical research and opinion, 2002, Volume: 18 Suppl 3 Topics: Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Humans; Quality of Life; Receptors, Dopam	2002
Switching to amisulpride. Current medical research and opinion, 2002, Volume: 18 Suppl 3 Topics: Amisulpride; Antipsychotic Agents; Humans; Patient Care Planning; Practice Guidelines as Topic; Prac	2002
Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia. International clinical psychopharmacology, 2002, Volume: 17 Suppl 4 Topics: Amisulpride; Animals; Antipsychotic Agents; Clinical Trials as Topic; Dopamine; Dose-Response Relati	2002
Pharmacological approaches to the management of schizophrenia. The Medical journal of Australia, 2003, 05-05, Volume: 178, Issue:S9 Topics: Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzothiaze	2003
Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature. Pharmacopsychiatry, 2004, Volume: 37, Issue:1 Topics: Adult; Amisulpride; Antipsychotic Agents; Body Weight; Clozapine; Dose-Response Relationship, Drug;	2004
Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. The international journal of neuropsychopharmacology, 2004, Volume: 7 Suppl 1 Topics: Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Dopamine Antagonists; Dopamine D2	2004
How do we choose between atypical antipsychotics? The advantages of amisulpride. The international journal of neuropsychopharmacology, 2004, Volume: 7 Suppl 1 Topics: Adverse Drug Reaction Reporting Systems; Amisulpride; Antipsychotic Agents; Clinical Trials as Topic	2004
[Current pharmacotherapy of schizophrenia]. Orvosi hetilap, 2004, Jan-18, Volume: 145, Issue:3 Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapin	2004
[The features of atypical neuroleptic amisulpride action]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2004, Volume: 104, Issue:6 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Clinical	2004
Consensus on the use of substituted benzamides in psychiatric patients. Neuropsychobiology, 2004, Volume: 50, Issue:2 Topics: Amisulpride; Antipsychotic Agents; Benzamides; Depressive Disorder; Humans; Mental Disorders; Schizo	2004
Amisulpride: a review of its use in the management of schizophrenia. CNS drugs, 2004, Volume: 18, Issue:13 Topics: Amisulpride; Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug	2004
Schizophrenia. Clinical evidence, 2003, Issue:10 Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Cognitive Behavioral	2003
Schizophrenia. Clinical evidence, 2004, Issue:12 Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Haloperidol; Humans;	2004
Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biological psychiatry, 2005, Jun-15, Volume: 57, Issue:12 Topics: Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Databases as Topic; Female; Human	2005
Schizophrenia. Clinical evidence, 2005, Issue:14 Topics: Amisulpride; Antipsychotic Agents; Chlorpromazine; Clozapine; Cognitive Behavioral Therapy; Dibenzot	2005
[Two cases of tardive Tourette syndrome]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, 2006, Volume: 108, Issue:5 Topics: Adult; Akathisia, Drug-Induced; Alcoholism; Amantadine; Antipsychotic Agents; Cholinergic Antagonist	2006
[The use of atypical antipsychotics in the long-term care of schizophrenia]. L'Encephale, 2006, Volume: 32 Pt 3 Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine;	2006
Atypical neuroleptics: clozapine and the benzamides in the prevention and treatment of tardive dyskinesia. Modern problems of pharmacopsychiatry, 1983, Volume: 21 Topics: Antipsychotic Agents; Benzamides; Clinical Trials as Topic; Clozapine; Dibenzazepines; Dose-Response	1983
Levosulpiride: a review of its clinical use in psychiatry. Pharmacological research, 1995, Volume: 31, Issue:2 Topics: Administration, Oral; Clinical Trials as Topic; Depressive Disorder; Dopamine Antagonists; Humans; I	1995
Sulpiride: an antipsychotic with selective dopaminergic antagonist properties. The Annals of pharmacotherapy, 1995, Volume: 29, Issue:2 Topics: Animals; Autonomic Nervous System Diseases; Basal Ganglia Diseases; Clinical Trials as Topic; Double	1995
[The place of amisulpride in the atypical neuroleptic class]. L'Encephale, 1996, Volume: 22 Spec No 2 Topics: Amisulpride; Animals; Depression; Humans; Limbic System; Neurologic Examination; Rats; Receptors, Do	1996
A risk-benefit assessment of sulpiride in the treatment of schizophrenia. Drug safety, 1996, Volume: 14, Issue:5 Topics: Antipsychotic Agents; Female; Humans; Male; Risk; Schizophrenia; Sulpiride	1996
Clinical update on amisulpride in deficit schizophrenia. International clinical psychopharmacology, 1997, Volume: 12 Suppl 2 Topics: Adult; Amisulpride; Antipsychotic Agents; Depression; Dose-Response Relationship, Drug; Double-Blind	1997
Amisulpride: from animal pharmacology to therapeutic action. International clinical psychopharmacology, 1997, Volume: 12 Suppl 2 Topics: Amisulpride; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Humans; Limbic System; Mice; Ra	1997
Safety of amisulpride (Solian): a review of 11 clinical studies. International clinical psychopharmacology, 1999, Volume: 14, Issue:4 Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Blood Cell Count	1999
Sulpiride for schizophrenia. The Cochrane database of systematic reviews, 2000, Issue:2 Topics: Antipsychotic Agents; Humans; Schizophrenia; Sulpiride	2000
Amisulpride: a review of its efficacy in schizophrenia. Acta psychiatrica Scandinavica. Supplementum, 2000, Volume: 400 Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chronic Disease; C	2000
Safety profile of amisulpride in short- and long-term use. Acta psychiatrica Scandinavica. Supplementum, 2000, Volume: 400 Topics: Amisulpride; Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Drug Administration Sc	2000
[New i.e. atypical neuroleptic agents for negative symptoms of schizophrenia: results and methodological problems of evaluation]. Der Nervenarzt, 2000, Volume: 71, Issue:5 Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins;	2000
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ (Clinical research ed.), 2000, Dec-02, Volume: 321, Issue:7273 Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Costs; Human	2000
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annual review of medicine, 2001, Volume: 52 Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins;	2001
[Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders]. Wiener klinische Wochenschrift, 2000, Dec-22, Volume: 112, Issue:24 Topics: Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Controlled Clinical Trials as T	2000
Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation? L'Encephale, 2000, Volume: 26 Spec No 1 Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Dose-Response Relationship, Drug; Humans; Psychiat	2000
Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia. Neuropsychobiology, 2001, Volume: 44, Issue:1 Topics: Adult; Aged; Amisulpride; Antipsychotic Agents; Double-Blind Method; Feasibility Studies; France; Hu	2001
Amisulpride: a review of its use in the management of schizophrenia. Drugs, 2001, Volume: 61, Issue:14 Topics: Acute Disease; Administration, Oral; Adsorption; Amisulpride; Antipsychotic Agents; Chronic Disease;	2001
Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biological psychiatry, 2001, Dec-01, Volume: 50, Issue:11 Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Models, N	2001
Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride. International clinical psychopharmacology, 2002, Volume: 17, Issue:1 Topics: Amisulpride; Antipsychotic Agents; Humans; Quality of Life; Schizophrenia; Schizophrenic Psychology;	2002
Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. The American journal of psychiatry, 2002, Volume: 159, Issue:2 Topics: Amisulpride; Antipsychotic Agents; Humans; Psychiatric Status Rating Scales; Randomized Controlled T	2002
Spotlight on amisulpride in schizophrenia. CNS drugs, 2002, Volume: 16, Issue:3 Topics: Amisulpride; Antipsychotic Agents; Humans; Schizophrenia; Sulpiride	2002
The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. Molecular psychiatry, 2002, Volume: 7, Issue:3 Topics: Amisulpride; Antidepressive Agents; Benzamides; Dysthymic Disorder; Humans; Receptors, Dopamine D1;	2002
Amisulpride for schizophrenia. The Cochrane database of systematic reviews, 2002, Issue:2 Topics: Amisulpride; Antipsychotic Agents; Humans; Randomized Controlled Trials as Topic; Schizophrenia; Sul	2002
Focus on amisulpride. Current medical research and opinion, 2002, Volume: 18, Issue:3 Topics: Amisulpride; Antipsychotic Agents; Controlled Clinical Trials as Topic; Dysthymic Disorder; Humans;	2002
New antipsychotics: classification, efficacy, and adverse effects. Schizophrenia bulletin, 1991, Volume: 17, Issue:2 Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Humans; Isoxazoles; Piperidines; Receptors	1991